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Description
[0001] The invention relates to the field of medicine and in particular to the treatment of ischemic disease and to
improving angiogenesis. The invention further relates to a method of culturing MSC, novel uses of phenanthroline in
replacing a missing biological structure, supporting a damaged biological structure and/or enhancing an existing biological
structure, and to novel medical products.
[0002] Angiogenesis, the formation of new blood vessels, is a physiological and vital process in growth and develop-
ment, as well as in wound healing. Wounds that are poorly vascularised and/or ischemic wounds heal slower, and
research has thus been directed towards inducing angiogenesis in, for instance, ischemic chronic wounds.
[0003] In contrast to the physiological and typically beneficial role, angiogenesis may also play a role in pathological
processes, such as cancer.
[0004] Thus, whereas anti-angiogenic therapies are generally being employed to fight cancer and malignancies, pro-
angiogenic therapies are generally explored as options to treat for instance cardiovascular diseases, graft survival, and
wound healing. Clinical research in therapeutic angiogenesis is ongoing for a variety of medical conditions. Presently,
three main categories of angiogenic methods are explored: gene therapy, protein therapy, and cell-based therapy.
[0005] There are, however still unsolved problems associated with angiogenic therapy. Gene therapy is, for instance,
hampered by difficulties in effective integration of the therapeutic genes into the genome of target cells, the risk of an
undesired immune response, potential toxicity, and oncogenesis related to the viral vectors used in gene therapy. It is
further questioned whether a single gene may be effective in restoring the defects in diseases that are multifactorial,
such as diabetes or heart disease. Cell-based angiogenic therapy, is still in an early stage of research, with questions
regarding the cell type to be used, obtaining the desired cell-type and post-transplant survival of the transplanted cells.
[0006] There is thus need for an alternative angiogenic therapy. An objective of the invention is to provide means and
methods for such alternative therapy.
[0007] In one embodiment, the invention provides a method for culturing mesenchymal stromal cell (MSC), the method
comprising
- providing a MSC; and
- culturing said MSC in the presence of 1, 10-phenanthroline or an active derivative thereof.
[0008] The invention provides the insight that a MSC, cultured in the presence of 1, 10-phenanthroline or an active
derivative thereof, but also a supernatant thereof, is for instance useful as a medicament for, amongst others, the
treatment of ischemia and/or for inducing angiogenesis.
[0009] In a preferred embodiment, a method according to the invention is provided, the method further comprising the
step of:
- harvesting the thus cultured cells and/or harvesting a supernatant thereof.
[0010] A mesenchymal stromal cell (MSC; synonyms: mesenchymal stem cell, marrow stromal cell, or multipotent
stromal cell) is a multipotent stem cell, which means that it is generally able to differentiate into different cell-types,
typically including osteoblasts (bone cells), chondrocytes (cartilage cells) and adipocytes (fat cells). However, a MSC is
typically not omnipotent, i.e. it does not have an unlimited repertoire. For instance, a MSC typically does not differentiate
into a cell of the myeloid lineage. MSC are present in many different tissues of the (human) body. A MSC can, for
instance, be obtained by bone marrow puncture, from adipose tissue, tendons, ligaments, umbilical cord blood, Wharton’s
Jelly, dental pulp, etc.
[0011] The International Society for Cellular Therapy has proposed the following minimal criteria for defining multipotent
MSC (25):
First, according to these minimal criteria, MSC is plastic-adherent when maintained under standard culture conditions.
Second, MSC express CD105 and CD90 and preferably also expresses CD73. MSC typically lack or are low for
expression of CD45, CD34, CD11b, CD19 and HLA-DR surface molecules and preferably also lack or are low for
expression of CD14 or CD79alpha.
Third, MSC are able to differentiate to osteoblasts, adipocytes and chondroblasts in vitro. In a preferred embodiment,
a method according to the invention is provided, wherein said a MSC is used, which is capable of adhering to plastic
when maintained under standard culture conditions. In a more preferred embodiment, a method according to the
invention is provided, wherein said MSC expresses CD105, CD73, and CD90 and lacks expression of CD45, CD34,
CD14 or CD11b, CD79alpha or CD 19, and HLA-DR surface molecules. Preferably, said MSC is capable of differ-
entiating to osteoblasts, adipocytes and chondroblasts in vitro.
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[0012] MSC can be obtained from a variety of different tissues. Sources for MSC include bone marrow, trabecular
bone, periosteum, articular cartilage, synovium, synovial fluid, muscle, adipose tissue, tendons, ligaments, blood, blood
vessels, umbilical cord vasculature, fetal tissue, skin, spleen, and thymus (59-61). In a preferred embodiment, a method
according to the invention is provided, wherein the MSC is obtained from bone marrow, tendon, ligament, bone, or
cartilage, more preferably from tendon or ligament. MSC are easily obtained from tendon or ligament, for instance by
performing a biopsy. Such ligament- or tendon-derived MSC, reviewed by Lui and Chan (60), are especially useful in
medical applications directed to tendon or ligament repair, but may also be used for other medical applications.
[0013] The term "culturing" is herein defined as maintaining MSC under suitable conditions, i.e. conditions that typically
allow a MSC to survive. Generally MSC are cultured in in a specially prepared nutrient medium at 37°C. However, for
shorter periods of time, it is also possible to culture MSC for instance in phosphate buffered saline, preferably comprising
nutrients such as glucose and minerals, or at lower temperatures. A person skilled in the art can easily determine suitable
conditions for culturing MSC for a predetermined period of time.
[0014] The term "supernatant" is herein defined as a liquid present above a (cell) sediment or a (cell) layer, said
sediment or layer preferably comprising a cell cultured in the presence of 1, 10-phenanthroline or an active derivative
thereof, more preferably comprising a MSC cultured in the presence of 1, 10-phenanthroline or an active derivative
thereof. In case of, for instance, an adherent cell (i.e. a cell that has adhered to a surface, typically a surface of, for
instance, a cell flask, petri-dish, or culture plate), the liquid that covers the cell during culture is the supernatant. Typically,
supernatant is a culture medium, preferably a pharmaceutically acceptable culture medium. However, especially for
short incubation times, physiologic saline or a buffered saline, is equally suitable. Any other liquid, suitable for culturing
a cell, preferably a MSC can be used in a method of the invention. In a preferred embodiment, a method according to
the invention is provided, wherein the supernatant is a (buffered) saline solution or a culture medium, preferably a culture
medium, more preferably a pharmaceutically acceptable culture medium.
[0015] The term "harvesting" is herein defined as the act or process of gathering (a) cell(s) or a supernatant from a
cell culture. Preferably, the cells cultured using a method according to the invention are harvested alive, i.e. in a vital
state. Harvesting of cultured cells can be done by a procedures known in the art, such as by using trypsine, a rubber
policeman, or a combination thereof. For harvesting a supernatant of the invention, it is not necessary that the cultured
cells survive, although it is preferred that the cells are not (extensively) damaged during the harvesting step. When cells
are damaged, they may release products, such as intracellular proteases, which may influence the quality of the super-
natant. Typically supernatant is harvested by decanting supernatant of a cell layer or pellet, optionally after a centrifugation
step.
[0016] 1, 10-phenanthroline, further referred to as "phenanthroline", is a hetero-aromatic compound having a formula
as depicted in Figure 5. Phenanthroline is capable of inducing HIF-1alpha activity in an human cervical cancer cell line
(28). Activation of HIF-1alpha activity is thought to be a result of the metal chelating properties of phenanthroline. It is
further thought that phenanthroline inhibits degradation of HIF-1alpha by virtue of chelation of the metal ion required for
catalytic activity of the proteolytic enzyme prolyl hydroxylase (58).
[0017] The term "active derivative" is herein defined as a compound having structural similarities, preferably having
a substituted backbone of phenanthroline. Preferably, an active derivative of phenanthroline has the same effect on
MSC, in kind, not necessarily in amount as 1,10-phenanthroline.
[0018] It is for instance generally possible to add substitutions to any one of the carbon atoms at the 2, 3, 4, 5, 6, 7,
8 and/or 9 position, without substantially losing the metal chelating properties of the phenanthroline backbone (23, 24).
[0019] Non-limiting examples of substituted phenanthroline derivatives are depicted in Figure 5. In addition to the
substituents depicted in Figure 5, other chemical groups, including sulfur, or amino substitutions and combinations of
any of the substituents are possible. In a preferred embodiment, a method according to the invention is provided, wherein
the active derivative has the same metal chelating activity, in kind, not necessarily in amount as phenanthroline. Preferably
the active phenanthroline derivative is substituted on the 2, 3, 4, 5, 6, 7, 8, and/or 9 position, more preferably on the 3,
4, 5, 6, 7, and/or 8 position, more preferably on the 4, 5, 6, and/or 7 position, most preferably on the 5 and/or 6 position.
Preferably a substitution reduces hydrophobicity, such that the compound is more easily soluble in water, or is more
stable in water.
[0020] It is also possible to use a derivative of phenanthroline substituted with a chemical reactive group, such as for
instance a sulfide, or a benzylic halogen. Such substituted phenanthroline is very useful for coupling to a matrix or a gel
or any other material for use in the invention. As implied in the term "active derivative", the thus coupled compound
preferably still has the same activity, in kind, not necessarily in amount, as phenanthroline. Preferably, the thus coupled
compound has the same metal chelating properties, in kind, not necessarily in amount, as phenanthroline.
[0021] In a preferred embodiment, a method according to the invention is provided, wherein said active derivative of
phenanthroline, is a phenanthroline compound substituted at the 2, 3, 4, 5, 6, 7, 8, and/or 9 position, preferably at the
3, 4, 5, 6, 7, and/or 8 position, more preferably at the 4, 5, 6, and/or 7 position, most preferably at the 5 and/or 6 position.
Preferably the substituent(s) are chosen, independently from one another from NO, OH, CH3, O, S, Br, Cl, and I. When
it is advantageous to reduce hydrophobicity, the substituent(s) are preferably chosen, independently from one another
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from NO, OH, O, and S. When substitution is performed in order to enable the compound to be coupled with for instance
a matrix or a gel, a substituent is preferably chosen from S, Br, Cl, and I.
[0022] MSC generally secrete a broad panel of growth factors and cytokines that have trophic properties (i.e. anti-
apoptotic and anti-inflammatory) (1). Several clinical trials have been completed or are currently on the way investigating
the use of MSCs for the treatment of, amongst others, autoimmune diseases (2-5), myocardial infarcts [reviewed in (6)],
solid organ/graft transplantations (7, 8) and ischemic wounds (9). Although differentiation of MSCs into cells of the target
tissue has been shown (10-12), the use of MSC for use in the above conditions generally results in low engraftment
percentages and there is only a short window in which effects are observed (13-16). The present invention now provides
a method for treating MSC such, that the resulting MSC and supernatant thereof have improved properties, such as for
instance improved angiogenic properties and/or improved graft survival.
[0023] In a preferred embodiment, a method for manufacturing phenanthroline treated MSC and/or supernatant thereof
is provided, for improving an angiogenic capacity of a MSC and/or a supernatant thereof. Said method preferably resulting
in a collection of cells and/or supernatant thereof with improved angiogenic capacity.
[0024] It is preferred to use primary MSC in a method of the invention, especially when the MSC themselves are to
be used for treating a subject. Preferably, a MSC used in a method according to the invention is obtained from the same
subject that is to be treated with a cell and/or supernatant obtained by a method according to the invention. This is called
an autologous transfusion. An autologous transfusion typically bears less risk of adverse reactions, such as for instance
a graft versus host reaction, than a heterologous transfusion (i.e. obtained from one subject and transfused to another
subject).
[0025] In a preferred embodiment, a method according to the invention is provided, wherein the MSC for use in the
method is a primary cell, preferably a human primary MSC. In another preferred embodiment, a MSC for use in a method
according to the invention is an immortalized MSC. Especially when supernatant is used, and not the cultured cells, it
is preferred to use immortalized MSC in a method according to the invention. Immortalized MSC are generally more
easily cultured and maintained than primary cells and typically secrete a similar cytokine/growth factor pattern. Super-
natant from immortalized cells is thus also suitable for treating a subject. When it is envisaged to treat a human subject
with cells and/or supernatant obtained by the method of the invention, a MSC to be used in the method is preferably a
human MSC. In a preferred embodiment, a method according to the invention is provided, wherein the MSC is a primary
MSC, preferably a primary human MSC.
[0026] In another preferred embodiment, a method according to the invention is provided, wherein the MSC is an
immortalized MSC, preferably an immortalized human MSC.
[0027] The invention shows in a working example that cells which are cultured for about 48 hours at a density of about
10,000 cells / cm2 with a concentration of about 200 mM phenanthroline show desirable characteristics. However, the
skilled person is quite capable of adapting these parameters for specific needs and for instance by increasing the cell
density and phenanthroline concentration or active derivative of phenanthroline, and at the same time decreasing contact
time, achieve similar results. In particular, concentrations of phenanthroline or an active derivative thereof are used that
show a desired effect (e.g. improved angiogenic capacity), without significantly inducing apoptosis.
[0028] In a preferred embodiment, a method according to the invention is provided, wherein the concentration of
phenanthroline or active derivative of phenanthroline in the culture is not more than 1 mM and not less than 1 uM.
Preferably the concentration of phenanthroline or active derivative of phenanthroline is between 10 uM and 1000 uM,
more preferably between 20 uM and 500 uM, more preferably between 50 uM and 300 uM, more preferably between
100 uM and 200 uM, most preferably between 150 and 200 uM.
[0029] In a preferred embodiment, a method according to the invention is provided, wherein said MSC are contacted
with said phenanthroline or an active derivative thereof at a cell density of at least 1,000 cell/cm2. Preferably, the cells
are contacted at a cell density of lower than 50,000 cells/cm2, more preferably between 2,000 - 20,000 cells/cm2, more
preferably between 5,000 - 15,000 cells/cm2, most preferably at about 10,000 cells/cm2.
[0030] In a preferred embodiment, a method according to the invention is provided, wherein the duration of contacting
said MSC with phenanthroline or the active derivative thereof is for at least 12 hours. Preferably, the MSC are contacted
with phenanthroline or an active derivative thereof for not more than 96 hours. More preferably, the MSC are contacted
with phenanthroline or an active derivative thereof for between 24 - 72 hours, more preferably for between 36 - 60 hours,
most preferably for about 48 hours.
[0031] Now that the invention provides a method for culturing MSC in the presence of phenanthroline or active derivative
of phenanthroline, the invention further provides a collection of cells or a supernatant obtainable by such method.
[0032] In one embodiment, the invention provides a collection of cells and/or a supernatant obtainable by a method,
the method comprising
- providing a MSC;
- culturing said MSC in the presence of phenanthroline or an active derivative thereof; and
- harvesting the thus cultured cell(s) and/or supernatant thereof.
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[0033] A collection of cells obtainable by a method according to the invention are distinguishable from other collection
of cells known in the art by their specific secretion pattern as described in the examples. The culture of cells for instance
comprises phenantroline or active derivative of phenanthroline cultured MSC cells that express VGEF and cells that
express IL-8 in an amount of at least 200 pg/ml culture supernatant per 48 hours of culture. The supernatant, comprising
proteins, such as growth factors and/or cytokines, secreted by the phenanthroline or active derivative thereof cultured
MSC, is thus also distinguishable from supernatants described before.. The supernatant for instance comprises super-
natant from phenantroline or active derivative of phenanthroline cultured MSC cells that comprises excreted VGEF and
excreted IL-8 in an amount of at least 200 pg/ml culture supernatant.
[0034] As said above, a cell obtainable by a method according to the invention preferably secretes different growth
factors and/or cytokines (i.e. the cell has changed its secretome) in respect to a MSC which has not been treated with
phenanthroline or an active derivative thereof. A cell obtainable by a method according to the invention, may also, but
not necessarily, express different cell-surface markers and, therefore, does not necessarily express all the markers, or
is not necessarily deficient in expression of all the markers as defined by the International Society for Cellular Therapy.
[0035] A cell obtainable by a method according to the invention is useful as a medicament, for instance, for treatment
of ischemia, for angiogenesis, in wound repair, in tendon and ligament regeneration, etc.
[0036] In one embodiment, therefore, the invention provides a collection of cells obtainable by a method according to
the invention for use as a medicament. In a preferred embodiment, the MSC cultured in a method according to the
invention is a huma MSC.
[0037] The invention further provides supernatant obtainable by a method according to the invention for use as a
medicament. Before use as a medicament, the supernatant is preferably concentrated in order to reduce the volume
and/or increase the concentration of, amongst others, growth factors and cytokines. Preferably, the supernatant is
concentrated such, that the volume is decreased without substantially altering the absolute amount of proteins, especially
growth factors and cytokines, present in the supernatant. It is also preferred that the concentration of proteins present
in the supernatant, relative to each other, remains essentially the same. Preferably, by concentrating a supernatant of
the invention, the supernatant is depleted from water, salts, glucose, and other small molecules present in the supernatant,
whereas larger proteins, like VEGF and IL8 are retained. Several methods for concentrating proteins in a supernatant
are known in the art and include, for instance, ultrafiltration, centrifugation (e.g. using a concentrator), freeze drying,
centrifugal evaporation, etc.
[0038] In a preferred embodiment, the invention provides a cell and/or supernatant obtainable by a method according
to the invention for use in the treatment of ischemia. By administering such cell or (concentrated) supernatant (or a
combination thereof) to a subject suffering from ischemia, the cell or supernatant will aid to the treatment of ischemia
and/or improve blood vessel formation.
[0039] In a preferred embodiment, the invention provides a cell, preferably a huma MSC, obtainable by a method
according to the invention and/or a supernatant obtainable by a method according to the invention, for inducing angio-
genesis. As shown by the present invention, a cell cultured in the presence of phenanthroline or an active derivative
thereof, but also a growth factor, such as VEGF and/or a cytokine, such as IL8, secreted by such cultured cell, will
increase angiogenic processes when administered to a subject in need of angiogenesis. By inducing angiogenesis, it
is for instance achieved that collateral veins are formed, which are able to short-circuit an obstructed or insufficient vein.
[0040] It is also possible to use of a cell or a supernatant obtainable by a method according to the invention in tendon
or ligament regeneration, as these biological structures are notorious for slow healing due to poor vascularisation. In a
preferred embodiment, a method according to the invention is provided, wherein the MSC is obtained from ligament or
tendon. It is especially useful to culture MSC obtained from ligament or tendon, when the thus cultured cells are to be
used for tendon or ligament regeneration. However, cells obtained by a method according to the invention, wherein the
MSC are obtained from ligament or tendon tissue, can also be used in other medical applications, such as wound repair,
improving transplant survival, etc.
[0041] In a preferred embodiment, a cell or supernatant obtainable by a method according to the invention is provided,
for use in tendon and/or ligament regeneration, preferably after tendon and/or ligament construction, more preferably
after anterior cruciate ligament construction. A cell and/or supernatant obtainable by a method according to the invention
enables improving vascularisation of the damaged tendon and/or ligament and consequently advances the healing
process of said tendon and/or ligament. When the thus cultured cells or supernatant thereof are to be used in tendon
and/or ligament regeneration, the method preferably comprises culturing of a ligament derived MSC or a tendon derived
MSC.
[0042] Further provided is a cell or a (concentrated) supernatant, obtainable by a method according to the invention
for use in wound healing. Standard treatment of (large) wounds is typically done by closing of the wound with a suture
and/or a patch. A cell and/or supernatant obtainable by a method according to the invention is very useful in such
situation. The wound can for instance, before closing, first be treated with a cell obtainable by a method according to
the invention. Also, direct application of supernatant from such cell is possible. It is, however, also possible to close the
wound with a suture and/or a patch comprising a cell obtainable by a method according to the invention. It is also possible
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to use a suture and/or a patch comprising a supernatant obtainable by a method according to the invention, or comprising
phenanthroline or an active derivative thereof.
[0043] A cell or a (concentrated) supernatant obtainable by a method according to the present invention is also very
useful for improving graft survival of for instance (allogenic) organ grafts or (allogenic) bone marrow grafts. Graft survival
is significantly improved when such graft is well vascularised. In case of a bone marrow graft, a cell or a (concentrated)
supernatant obtainable by a method according to the invention preferably improves survival of the transplanted bone
marrow cells. Without being bound to theory, a growth factor and/or cytokine secreted by the cell and/or present in the
supernatant may inhibit apoptosis of the grafted cells. Also for artificial grafts that have been shaped in vitro, such as
for instance tissue engineered constructs (e.g. skin appendices, bone structures, etc.), a cell or supernatant obtainable
by a method according to the invention is especially useful.
[0044] In a preferred embodiment, a cell or a supernatant obtainable by a method according to the invention is provided,
for use in improving graft survival, preferably for use in improving organ or bone marrow graft survival.
[0045] In another preferred embodiment, a cell or a (concentrated) supernatant obtainable by a method according to
the invention is provided, for use in the treatment of osteoporosis and/or bone fractures.
[0046] Now that the invention provides the insight that a MSC cultured in the presence of phenanthroline is useful for
treating a variety of diseases, in particular diseases related to angiogenesis, the invention further provides the use of
phenanthroline or an active derivative thereof for improving the angiogenic properties of MSC and/or supernatant thereof.
Also provided is the use of phenanthroline or an active derivative thereof for inducing endothelial differentiation in MSC.
It is preferred to improve the angiogenic properties of MSC and/or supernatant thereof, or induce endothelial differentiation
in MSC in vitro. The invention further provides the use of a cell or a culture supernatant obtainable by a method of the
invention for the recruitment of endothelial cells, smooth muscle cells or pericytes to the inoculation site.
[0047] In another embodiment, the invention provides the use of a cell and/or supernatant obtainable by a method
according to the invention, or phenanthroline or an active derivative thereof for improving the angiogenic properties of
medical implants. Such medical implant is for instance an artificial bone or joint structure, such as a hip prosthesis or
cartilage, or a skin transplant or a stent. By incorporating a cell and/or supernatant obtainable by a method according
to the invention, or phenanthroline or an active derivative thereof in such medical implant, angiogenic properties of such
medical implant is improved and vascularisation will be improved after implantation. Consequently the implant is more
likely to be accepted by the recipient and incorporated within the surrounding biological structures.
[0048] A cell or a (concentrated) supernatant obtainable by a method according to the invention can for instance be
incorporated in a scaffold (e.g. calcium phosphate ceramic scaffold, electrospun fibre, 3D printed scaffold) or a coating
(e.g. calcium phosphatate coating and derivatives) or be used for tissue regeneration (e.g. incorporated in an (artificial)
tendon or ligament to be used in tendon and ligament reconstruction, skin transplants, etc.). In another embodiment,
the invention provides a cell and/or supernatant obtainable by a method according to the invention, or phenanthroline
or an active derivative thereof for treating diabetes, preferably by improving graft survival of Islets of Langerhans. Lang-
erhans’ cells are generally transplanted via portal vein injection, but their survival is generally compromised by lack of
vascularisation. For instance, incorporation of islets in a gel containing phenanthroline or an active derivative thereof,
or a cell or supernatant obtainable by a method according to the invention improves angiogenesis and therefore increases
graft survival and activity.
[0049] Now that the invention provides the insight that a cell and/or supernatant cultured in the presence of phenan-
throline or an active derivative thereof is useful in the treatment of several conditions, such as ischemia, wound healing
and tendon damage, the invention further provides a method for treating a subject, the method comprising: administering
to said subject, preferably a human subject, a suitable amount of phenanthroline or an active derivative thereof, or a cell
or a supernatant obtainable by a method according to the invention. Such treatment preferably results in less ischemic
damage, accelerated wound healing and/or angiogenesis. In a preferred embodiment, said subject is suffering from or
is at risk of suffering from ischemia. Preferably, the cell or supernatant is obtainable by a method according to the
invention, wherein the method makes use of a huma MSC, more preferably a primary huma MSC, most preferably
obtained from the subject to be treated.
[0050] In a preferred embodiment, a method for treating a subject in need of angiogenesis is provided, the method
comprising administering to said person a suitable amount of phenanthroline or an active derivative thereof, or cells
and/or supernatant obtainable by a method according to the invention. A subject in need of angiogenesis is for instance
a subject suffering or at risk of suffering from heart disease. It is beneficial that novel arteries and veins are formed that
replace arteries and veins that are (partially) obstructed. As described, a method according to the invention preferably
results in such novel arteries and veins by inducing angiogenesis in a subject in need thereof.
[0051] In yet another preferred embodiment, a method for treating a subject in need of wound repair and/or tendon
regeneration and/or ligament regeneration is provided, the method comprising administering to said person a suitable
amount of phenanthroline or an active derivative thereof, or cells and/or supernatant obtainable by a method according
to the invention. Preferably, the step of administering comprises suturing the wound, tendon and/or ligament with a
suture and/or a patch comprising a cell or supernatant obtainable by a method according to the invention, and/or com-
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prising phenanthroline or an active derivative thereof. Such method preferably results in improved vascularisation of the
wound edges, tendon and/or ligament, which subsequently leads to improved healing of the wound, ligament and/or
tendon.
[0052] In (chronic and/or ischemic) wound healing, a cell and/or a supernatant obtainable by a method according to
the invention is especially useful. Such cell can for instance be applied directly into the wound, but it is also possible to
cover the wound with a wound dressing comprising such cell. Of course, a supernatant obtainable by a method according
to the invention can also be incorporated in the wound dressing. It is also possible to provide a wound dressing comprising
phenanthroline or an active derivative thereof. Without being bound to theory, it is believed that such wound dressing,
when placed on the wound, attracts MSC from other sites of the body, for instance from the bone marrow, to the wound.
Near the wound, the MSC come into contact with phenanthroline or the active derivative thereof and as a result will
improve their angiogenic property. Such wound dressing comprising phenanthroline or an active derivative thereof thus
improves wound healing. Of course, it is also possible to provide the wound dressing with both, MSC and phenanthroline
or an active derivative thereof, such that MSC not necessarily first have to be attracted from another site of the body.
[0053] It can also attract already differentiated endothelial cells as well as smooth muscle cells or even pericytes.
Recruitment of endothelial cells in vivo by a means or method of the invention is important. However, other cell types
can be recruited to make a functional blood vessel.
[0054] The invention thus provides a wound dressing for accelerating the healing process of a wound, the wound
dressing comprising a cell and/or a supernatant obtainable by a method according to the invention, and/or phenanthroline
or an active derivative thereof.
[0055] Further provided is a method for accelerating the healing process of a wound, the method comprising applying
to said wound, a wound dressing according to the invention, or a cell and/or supernatant obtainable by a method according
to the invention. Such wound dressing will significantly improve wound healing as a result of its ability to improve
angiogenic properties within the wound.
[0056] Especially in chronic and/or ischemic wounds it is important to induce angiogenesis. In a preferred embodiment,
a method for accelerating the healing process of a wound according to the invention is provided, wherein said wound
is a chronic wound and/or wherein said wound is an ischemic wound.
[0057] In a preferred embodiment the invention provides a cell or a culture supernatant obtainable by a method of the
invention for the use in the treatment of damage to the hart following a stroke or other ischemic event. In a referred
embodiment said cell or culture supernatant obtainable by a method of the invention is used in cardiac repair following
an ischemic event,, preferably stroke.
[0058] The invention further provides a medical product, such as a graft, a (micro)pump, an implant or a wound
dressing, comprising phenanthroline or an active derivative thereof, a cell, preferably a human cell, obtainable by a
method according to the invention, and/or a supernatant obtainable by a method according to the invention. In a preferred
embodiment, a medical product according to the invention is provided, wherein the medical product is a medical implant,
such as for instance a prosthesis, coated with phenanthroline or an active derivative thereof, or a cell and/or supernatant
obtainable by a method according to the invention.
[0059] In another preferred embodiment, a medical product according to the invention is provided, wherein the medical
product is a suture or a patch comprising phenanthroline or an active derivative thereof, or a cell and/or supernatant
obtainable by a method according to the invention. The use of such suture or patch has the advantage that the edges
of the wound are in close contact with phenanthroline or the active derivative, the cell or with factors, present in the
supernatant, secreted by such cell. This preferably leads to increased vascularisation of the wound edges and faster
healing of the wound.
[0060] In a further preferred embodiment, a medical product according to the invention is provided wherein the medical
product is an implant or graft. The invention thus provides an implant or a graft for transplantation, comprising phenan-
throline or an active derivative thereof, or a cell and/or supernatant obtainable by a method according to the invention.
It is possible to apply or provide the graft with phenanthroline or the active derivative, or with such cell or (concentrate)
of such supernatant (just) before the graft or transplant is transplanted, but it is also possible to culture the graft or implant
in the presence of phenanthroline or the active derivative, the supernatant, and/or together with the MSC for a specific
period of time, preferably about 48 hours before transplanting the implant or graft into a recipient.
[0061] In a preferred embodiment, the graft for transplantation comprises Langerhans’ cells. In yet another preferred
embodiment, a medical product according to the invention is provided, wherein the medical product is a pump, preferably
a micropump, comprising phenanthroline or an active derivative thereof, or a cell and/or supernatant obtainable by a
method according to the invention. Suitable pumps, such as for instance osmotic or matrix gel pumps, are known in the
art (55). Such pump comprising phenanthroline or an active derivative thereof, or a cell or a (concentrated) supernatant
obtainable by a method according to the invention enables continuous administration of said cell or said supernatant to
a person in need thereof. Such pump may, for instance, be inserted after surgery in order to provide the compound(s),
cells or supernatant in the vicinity of a wound and, consequently, increase wound healing and/or vascularisation.
[0062] The invention thus provides a medical product for use in a medical treatment, the medical product comprising
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phenanthroline or an active derivative thereof, or a cell or a (concentrated) supernatant obtainable by a method according
to the invention. Preferably, the medical product comprises a cell or a supernatant obtainable by a method according to
the invention, most preferably the medical product comprising a cell obtainable by a method according to the invention.
Preferably such medical product is used for replacing a missing biological structure, supporting a damaged biological
structure, or enhancing an existing biological structure.
[0063] Also provided is a method for replacing a missing biological structure, supporting a damaged biological structure,
and/or enhancing an existing biological structure, the method comprising the use of a cell, preferably a human cell,
obtainable by a method according to the invention, a supernatant obtainable by a method according to the invention,
phenanthroline and/or an active derivative thereof, and/or a medical product according to the invention, to replace,
support and/or enhance a biological structure. A biological structure is defined herein as any biological structure, ranging
from a thin cell layer, such as for instance cartilage or skin, to a complete organ, such as for instance a heart or (part)
of a liver. The biological structure may be present in a living (human) body, but may also be an in vitro engineered
biological structure in, for instance, a petri-dish.
[0064] Because previous screening methods were based mostly on cancer cells and the results thereof can not
necessarily be extrapolated to MSC, a novel screening method was developed, based on an immortalized MSC. Using
this screening method, we quickly screened a large panel of potential compounds for effects on MSC. Such screening
method is useful for screening a large panel of compound for their ability to modulate (i.e. increase or decrease) an
angiogenic capacity of a MSC.
[0065] The invention further provides a method for screening whether a compound is able to modulate an angiogenic
capacity of a MSC, the method comprising
- providing a MSC with a construct comprising an hypoxia response element operably linked to a reporter gene;
- contacting said MSC with the compound; and
- detecting whether said reporter gene is transcribed,
- wherein the transcription of said reporter gene is indicative for whether said compound is able to modulate an
angiogenic capacity of a MSC.
[0066] In a preferred embodiment, the MSC is a huma MSC, preferably an immortalized MSC. A compound that is
able to improve (i.e. increase) an angiogenic capacity of a MSC preferably induces transcription of said reporter gene,
whereas a compound which is capable of decreasing an angiogenic capacity of a MSC preferably inhibits transcription
of said reporter gene. It is of course also possible to test a combination of compounds for their synergistic or antagonistic
properties with regard to the angiogenic properties of a MSC.
[0067] A MSC used in a screening method according to the invention can be obtained from the various tissues as
described above. Preferably, the MSC used in a screening method according to the invention is a ligament- or tendon-
derived MSC. Such cell is especially useful for screening for compounds that are capable of improving ligament or tendon
regeneration. Preferably, such MSC is immortalized before being used in a screening method according to the invention.
[0068] It is possible to use for instance an (immortalized) MSC and transfect it with a HRE-luciferase construct as
described in Said et al (56) or with a 5HRE-ODD-luc construct described in Saha et al (57). Detection of transcription
of the reporter gene is then easily achieved by measuring luciferase activity (luminescence) of the cells after contacting
said MSC with the compound. A compound which is able to improve angiogenic capacity of a MSC, preferably induces
transcription of the reporter gene through the hypoxia responsive element. As a consequence, reporter gene expression
is increased, which can be detected, in case of luciferase, by measuring an increase in luminescence in these cells.
Vice versa, decreased luminescence is indicative for a compound able to inhibit angiogenesis, which compound may
subsequently be used for anti-angiogenic therapy, for instance in anti-tumor therapy.
[0069] The invention is further explained and exemplified by the following non-limiting examples.
Figure legends
[0070]
Figure 1. Phenanthroline induces strong expression of HRE-containing genes, compared to DFO and hy-
poxia culture. Primary MSCs were cultured in the presence of 150 mM DFO, 200 mM PHE or in an hypoxia chamber
(2% O2). After 2 days, whole genome expression analysis was performed and the expression of known HRE-
containing genes was examined. Of the three culture methods, most genes were strongest induced using PHE.
Heatmaps show the relative expression of denoted genes compared to cells in basic medium, with all genes statis-
tically significant regulated compared to cells in basic medium (P<0.05). The relative expression data are also
depicted in table Table 2.
Figure 2. Phenanthroline induces secretion of IL-8, but DFO induces higher secretion of VEGF. Primary MSCs
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were cultured in the presence of 150 mM DFO, 200 mM PHE or in a hypoxia chamber (2% O2) for 2 days, after which
cells were lysed. Protein concentrations of IL-8, VEGF, bFGF and G-CSF were determined in cell lysates and as
shown, only phenanthroline induced secretion of high levels of Il-8, which were not affected by DFO or hypoxia
culture. In contrast, VEGF secretion was increased by all three culture methods, but highest by DFO. D231 and D
142; donor number as specified in the laboratory database, (*) denotes P<0.05, (**) denotes P<0.01, (##) denotes
P<0.01 compared to basic, DFO and hypoxia (one-way Anova and Tukey’s test).
Figure 3. Conditioned medium enhances proliferation and sprouting. Conditioned medium was prepared by
culturing cells in the presence of 150 mM DFO, 200 mM PHE or in a hypoxia chamber (2% O2), after which the
medium was changed and cells were kept in culture for 2 more days. As a control non-treated cells were incubated
with medium. Conditioned medium was used to culture HUVECs and MSCs and proliferation was determined by
counting the cell number or measuring metabolic activity, respectively. a, proliferation of MSCs was significantly
increased by PHE-CM, but not by other types of CM, although there was no significant difference between PHE-
CM and other CM. (*) denotes P<0.05, (One-way Anova and Tukey’s test). b, in contrast, proliferation of HUVECs
was significantly increased by DFO-, PHE- and hypoxia-CM. c, gene expression analysis of sprouted HUVECs on
matrigel showed that expression of endothelial genes was increased by DFO-CM, PHE-CM and hypoxia-CM, com-
pared to basic- and non-CM. VWF; von Willebrand factor, eNOS; endothelial nitric oxide synthase, VECad; VE
cadhering, VEGF; vascular endothelial growth factor, Tie 1; tyrosine kinase receptor, KDR; kinase insert domain
receptor, (*) denotes P<0.05 compared to basic-CM (One-way Anova and Tukey’s test).
Figure 4. Cell migration is enhanced by conditioned medium. Conditioned medium was prepared by culturing
cells in the presence of 150 mM DFO, 200 mM PHE or in a hypoxia chamber (2% O2), after which the medium was
changed and cells were kept in culture for 2 more days. As a control non-treated cells were incubated with medium.
Conditioned medium was then used to culture HUVECs and MSCs for a scratch wound healing assay. Migration of
cells was increased in conditioned medium, but no differences between these types of conditioned medium were
observed, although migration of HUVECs in PHE-CM seemed to be slightly enhanced.
Figure 5. In vivo capillary ingrowth in matrigel containing DFO or PHE. Matrigel plugs (0.5 ml) containing either
PBS , DFO (150 uM) or PHE (200 uM) were injected subcutaneously and analyzed for capillary ingrowth after 7
days. a, vessel ingrowth was scored in a categorical way and expressed as mean 6 SEM per group (n=7) in arbitrary
units (AU). b, the endothelial nature of the ingrowing cells structures is confirmed by CD31 staining. c, in two plugs
in the PHE treated group extraordinary ingrowth of capillary like structures throughout the total plug could be observed,
demonstrated a clear lumen surrounded by CD31 positive cells.
Figure 6. Chemical formula of 1,10-phenanthroline and chemical formulas of examples of substituted de-
rivatives.
Figure 7. Quinacrine hydrochloride does not affect VEGF gene expression. Primary MSCs were cultured in
the presence of quinacrine hydrochloride (1 nM, 10 nM and 1 uM) for 2 days, after which VEGF gene expression
was determined by qPCR. None of these concentrations increased VEGF expression.
Figure 8. Expression of HRE-responsive genes is stably enhanced by PHE. Primary MSCs were cultured in
the presence of DFO, PHE or in an hypoxia chamber for 2 days. After refreshing the medium and 2 more days of
culture in basic medium, expression of Il-8, VEGF, KDR and Foxc2 was examined. Only after treatment with PHE
expression of these genes was still significantly increased, whereas in DFO and hypoxia cultures expression levels
had returned to basal levels.
Examples
Materials and methods
Cell culture
[0071] Bone marrow aspirates (5-15mL) were obtained from patients with written informed consent and isolated as
previously described (50). Human mesenchymal stromal cells (MSCs) were expanded in proliferation medium consisting
of alpha minimal essential medium (alpha-MEM; Gibco, Carlsbad, CA), 10% fetal bovine serum (Lonza, Verviers, Bel-
gium), 0.2 mM ascorbic acid (Sigma Aldrich, St. Louis, MO), 2 mM L-Glutamine (Gibco), 100 U/mL of penicillin and 100
mg/mL of streptomycin (Invitrogen, Carlsbad, CA) and 1 ng/mL of basic fibroblast growth factor (bFGF, Instruchemie,
Delfzijl, The Netherlands). Basic medium consisting of proliferation medium without bFGF was used during the experi-
ments. Human umbilical vein endothelial cells (HUVECs) were commercially obtained from Lonza and cultured in En-
dothelial Growth Medium-2 (EGM-2) with addition of the microvascular bullet kit (MV, all from Clonetics, Lonza), containing
hEGF, hydrocortisone, gentamicin, 5% FBS, VEGF, hFGF-B, R3-IGF-1 and ascorbic acid. Cells were kept at 37°C and
5% CO2. Medium was refreshed three times per week and cells were trypsinised when a confluency of 70-80% was
reached.
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Conditioned medium preparation
[0072] To prepare conditioned medium (CM), MSCs were cultured until near confluency in proliferation medium. Then,
medium was changed to basic medium (basic-CM), basic medium supplemented with 150 mM DFO (DFO-CM) or 200
mM PHE (PHE-CM) or cells were added to a hypoxia chamber (2% O2). After 2 days of culture, medium was removed
and cells were washed with PBS twice, after which serum-free basic medium was added and cells were kept in culture
for 2 more days. Then, CM was collected and centrifuged at 900g for 5 minutes to remove cell debris. CM was directly
applied to target cells. As a control, serum free medium that had not been in contact with any cells was used (non-CM).
For HUVECs, a 7:3 mixture of CM and EGM-2 was used.
Gene expression analysis
[0073] MSCs were seeded in triplicate in 6-well plates at 5000 cells/cm2 and allowed to attach for 10-15 hours in
proliferation medium. Upon reaching near confluency, cells were treated as described above. After 2 days of treatment
and 2 subsequent days of incubation with fresh medium, cells were lysed immediately with TRIzol. RNA was isolated
using a Bioke RNA II nucleospin RNA isolation kit (Machery Nagel) and RNA concentrations were measured using an
ND100 spectrophotometer (Nanodrop technologies, USA). cDNA was synthesized from 100 ng of RNA, using iScript
(BioRad) according to the manufacturer’s protocol. For qualitative PCR, a master mix, containing distilled water, forward
primer, reverse primer (Sigma Genosys), BSA, and SYBR green I mix (all from Invitrogen) was prepared. Real-time
qPCR was performed in a Light-Cycler (Roche). Light-Cycler data was analyzed using the fit points method of Light-
Cycler software. The baseline was set at the lower log-linear part above baseline noise and the crossing temperature
(Ct value) was determined. Ct values were normalized to the 18S housekeeping gene and delta Ct (Ct, control ⎯ Ct, sample)
was used to calculate the upregulation in gene expression (53). Primer sequences are listed in table 1.
Protein expression analysis
[0074] MSCs were seeded at 5000 cells/cm2 in T25 flasks. Upon reaching near-confluence, medium was changed
for basic medium, basic medium with 150 mM DFO or 200 mM PHE or cells were added to a hypoxia chamber (2% O2).
After 2 days, cells were lysed with 250 mL RIPA buffer with addition of protease/phosphatase inhibitors (Roche). Total
protein concentrations were determined using a BCA kit (Pierce) and 10 mg of total protein was used to determine
concentrations of VEGF, IL-8, basic fibroblast growth factor (bFGF), growth-colony stimulating factor (G-CSF) and
epidermal growth factor (EGF) using a Luminex assay (Invitrogen) according to the manufacturer’s protocol. Briefly,
cells and standards were incubated with fluorescent beads, followed by incubation with a biotinylated detection antibody.
After incubation with streptavidin-R-Phycoerythrin and washing, both the fluorescence of the coupled beads and the R-
phycoerythrin were measured using a Luminex® FlexMap™.
Whole genome expression analysis
[0075] MSCs were seeded in T25 flasks at 5000 cells/cm2 and allowed to attach overnight in proliferation medium.
The next day, medium was added with the following conditions; basic medium, basic medium supplemented with 150
uM DFO or basic medium supplemented with 200 mM PHE. After 48 hours, RNA was isolated as described above. From
500 ng of RNA, cRNA was synthesized using the Illumina TotalPrep RNA amplification Kit (Ambion), according to the
manufacturer’s protocol and the quality of RNA and cRNA was verified on a Bioanalyzer 2100 (Agilent). Microarrays
were performed using Illumina HT-12 v4 expression Beadchips, according to the manufacturer’s protocol. Briefly, 750
ng of cRNA was hybridized on the array overnight after which the array was washed and blocked. Then, by addition of
streptavidin Cy-3 a fluorescent signal was developed. Arrays were scanned on an Illumina iScan reader and raw intensity
values were background corrected in GenomeStudio (Illumina). Further data processing and statistical testing were
performed with R and Bioconductor statistical software (www.bioconductor.org), using package lumi. Raw intensity
values were transformed using variance stabilization and a quantile normalization was performed. A linear modelling
approach with empirical Bayesian methods, as implemented in Limma package (54), was applied for differential expres-
sion analysis of the resulting probe-level expression values. A gene list, containing only those genes with an absolute
1.5-fold change between different treatments, was uploaded to Ingenuity Pathway Analysis (IPA) software and used for
core analysis. Pathways or networks with a p-value of 0.05 were considered statistically significant.
Proliferation
[0076] MSCs and HUVECs were seeded in triplicate in 6-well plates at 3,000 cells/cm2 and allowed to attach overnight
in denoted culture medium. Then, cells were washed and conditioned medium was added. After 3 days, proliferation of
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MSCs was determined by measuring the metabolic activity using a 10% (v/v) Alamar Blue (Invitrogen) and for HUVECs,
nuclei were stained with DAPI (Sigma Aldrich) and counted.
Scratch wound healing assay
[0077] HUVECs were seeded in triplicate in 6-well plates at 10,000 cells/cm2 and allowed to attach for 10 to 15 hours
in denoted culture medium. When the cells reached near confluency, a wound was created by scratching the surface
with a pipet tip, and the medium was changed to different types of conditioned medium. After 12 and 20 hours pictures
were taken to examine migration of cells into the wound.
[0078] HUVEC gene expression profile6-well plates were coated with 1 mL of a 1:1 mixture of ice-cold Matrigel (Bio-
sciences) and endothelial basic medium (EBM, Lonza). Plates were kept at 37 °C for at least 30 minutes to allow
solidification of the Matrigel. Then, HUVECs in passage 2-3 were trypsinized, resuspended in endothelial growth medium-
2 (EGM2) (Lonza) and seeded onto the Matrigel at 500,000 cells/well in a volume of 600 mL. Conditioned medium was
prepared as described and 1.4 mL of denoted conditioned medium + 0.6 mL of EGM-2 was added to each well. After
24 hours cells were lysed using TRIzol for RNA isolation as described above.
In vivo murine matrigel plug assay
[0079] In vivo angiogenesis analysis was performed using a matrigel plug assay in male C57/BL6 mice (age 8 weeks)
(Charles River). Growth factor reduced matrigel (0.5 ml) (BD Biosciences) was injected into the subcutaneous space
on the dorsal side of mice on both the left and right flank. Matrigel was mixed at 4 °C with PBS, DFO (150 uM) or PHE
(200 uM) (n=7 mice per group). Mice were sacrificed 7 days post-implantation. Matrigel plugs were excised and processed
for histological analysis. Paraffin sections (5 um) were stained with Hematoxylin, Phloxine and Saffron (HPS) or anti-
CD31 (PECAM, Abcam, Cambridge, UK). Vascular ingrowth was scored in a double blinded fashion and quantified using
the following method: every individual section was scored for the degree of ingrowth, using five different categories of
ingrowth (1=minimal ingrowth at the border of the plug, 5=capillary ingrowth throughout the total plug), and the mean
ingrowth score per group was defined (6 sections per plug, 7 mice per group). The endothelial nature of the infiltrating
cells was confirmed by the CD31 staining,
Statistics
[0080] Data was analyzed using one-way ANOVA followed by Tukey’s multiple comparison’s test (P<0,05). For the
analysis of the ingrowth in the matrigel plug statistical analysis was performed using ANOVA and unpaired T test.
Results
Phenanthroline induces expression and secretion of angiogenic growth factors
[0081] To identify differences between the known hypoxia mimic DFO and PHE, we performed a whole genome
expression analysis of MSCs treated for two days and compared this with cells grown under standard hypoxia conditions
(2% O2). Heatmaps in figure 1 show the expression levels of previously identified HRE-containing genes (31), grouped
by function. Both DFO and PHE increased expression of genes involved in metabolism, cell growth and survival as well
as endothelial genes, but PHE markedly induced higher expression. Expression of various known hypoxia-responsive
genes was increased by hypoxia culture, but expression of these genes was markedly higher after treatment with DFO
or PHE. Interestingly, interleukin-8 (Il-8) was highly induced by PHE (top gene), whereas DFO and hypoxia did not affect
this gene at all.
[0082] We then examined the secretion of angiogenic factors at a protein level, including IL-8 and VEGF and, as
shown in figure 2, PHE indeed increased the secretion of IL-8 to 300-500 pg/mL, whereas in DFO and hypoxia-treated
cells IL-8 levels were comparable to basic (15-25 pg/mL). In contrast, although VEGF secretion was induced by all three
treatments, it was higher in DFO-treated cells (140 pg/mL) than in PHE-treated cells (65 pg/mL), even though microarray
data showed higher expression of VEGF after treatment with PHE. In contrast, secretion of growth-colony stimulating
factor (G-CSF) and basic fibroblast growth factor (bFGF) was reduced by PHE-treatment compared to DFO and hypoxia.
To investigate if these secreted growth factors exert trophic effects, conditioned medium (CM) was prepared from DFO-,
PHE- or hypoxia-treated MSCs, which was then used to culture fresh HUVECs and MSCs. After 2 days of treatment
and 2 more days of incubation with fresh medium, VEGF was still highly expressed in PHE-treated cells, whereas
expression levels in DFO- or hypoxia-treated cells were comparable to non-treated cells (Figure 8). However, PHE-CM
did not increase proliferation of HUVECs or MSCs, compared to basic- or hypoxia-CM (figure 3A and 3B), although in
MSCs, PHE-CM was the only medium to significantly increase proliferation compared to non-CM. To investigate the
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effect of secreted factors on sprouting of HUVECs, cells were seeded on Matrigel in different types of conditioned medium
(CM). As shown in figure 3C, whereas expression of endothelial genes was slightly decreased in basic-CM, DFO-CM
and PHE-CM increased expression of these genes and demonstrated similar effects as hypoxia-CM. Similarly, a scratch
wound healing assay demonstrated that migration of both HUVECs and MSCs was increased by CM, but no differences
were observed between these groups, although for HUVECs, migration seemed slightly increased in DFO- and PHE-
CM (Figure 4).
Phenanthroline enhances in vivo blood vessel formation
[0083] Ultimately, we tested the efficacy of DFO and PHE as factors that can stimulate the hypoxia driven angiogenic
response in vivo by incorporating DFO (150 uM) or PHE (200 uM) in matrigel plug that are injected subcutaneously in
mice. After 7 days a significantly increased capillary ingrowth could be observed in the DFO treated as well as the PHE
treated mice (Figure 5). The ingrowth in DFO and PHE did not differ significantly, however it should be noted that in the
PHE-treated group two mice showed excessive capillary ingrowth that resulted in the presence of capillary structures
throughout the total plug (Figure 5C).
Discussion
[0084] Here we show that treatment of MSCs with such a small molecule, PHE, results in enhanced secretion of VEGF,
compared to hypoxia treatment and in addition, enhances vessel formation in vivo and results in high protein levels of
Il-8, which is involved in proliferation, survival, sprouting and angiogenesis (48). The stronger effects of chemical hypoxia
might be the result of the severity of the hypoxia stimulus, which in turn results in a more sustained response. Our data
shows that PHE offers a cheap and easy alternative for hypoxia cultures and in addition, PHE can be applied directly
in an in vivo setup, such as in a matrigel plug. The effects of PHE-conditioned medium on proliferation and sprouting of
HUVECs were comparable to those of hypoxia-conditioned medium. Dissolving the compound in water, opposed to the
DMSO used here, is likely to reduce the inhibitory effect of PHE on proliferation and improve therapeutic value further.
Compared with DFO, PHE treatment had similar effects, but the stronger activation of HIF target genes by PHE shows
that this compound is more potent, which is partially reflected in the matrigel plug assay, where PHE enhanced capillary
growth in two out of 7 mice.
[0085] Whole genome analysis showed that, although DFO and the hypoxia incubator increase expression of several
hypoxia target genes, only MSCs exposed to PHE showed a dramatic increase in IL-8 expression. Although described
to be upregulated by hypoxia in endothelial cells and fibroblasts (42, 43), IL-8 can also be induced by hypoxia-independent
mechanisms. Without being bound by theory, a hypothesis for the increase of IL-8 solely in PHE-treated cells could be
that PHE activates another signaling pathway that in turn activates IL-8 transcription. A candidate pathway is the NF-
κB pathway, which activation leads to IL-8 expression (44, 45). Indeed, our microarray data shows that expression of
RelA - a NF-κB target gene - is higher in the presence of PHE than in hypoxia or DFO-treated cells. Alternatively,
increased stability of the heterodimeric complex in the nuclei may explain the stronger activation of HIF target genes,
as we also observed a higher expression of P300, a known co-activator of HIF, in PHE-treated cells (21, 46).
[0086] Previously, several screens for HIF activation/inhibition have been performed. We used a clonally expanded
immortalized MSC cell line reasoning that, the cellular components of the hypoxia pathway will closely resemble those
in primary MSCs (39). Surprisingly, of the 12 previously identified hypoxia mimics (28), only phenanthroline or active
derivative thereof was able to mimic hypoxia in MSCs. This demonstrates that cell type can be important in regulating
hypoxia.
[0087] We tested the response to the above-mentioned treatments in MSCs from two different donors and found that
the expression profile was highly reproducible.
Table 1. Primer sequences
Gene Forward primer Reverse primer
18S CGGCTACCACATCCAAGGAA GCTGGAATTACCGCGGCT
VEGF-A Commercially obtained from SA biosciences
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Table 2. Relative gene expression data
Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_1707727 ANGPTL4 NM_139314.1 51129 7,28 7,33E-28
ILMN_2184373 IL8 NM_000584.2 3576 6,28 1,10E-25
ILMN_1756573 NDUFA4L2 NM_020142.3 56901 5,61 1,52E-25
ILMN_1784294 CPA4 NM_016352.2 51200 5,44 2,81E-27
ILMN_1666733 IL8 NM_000584.2 3576 5,35 1,98E-25
ILMN_2186061 PFKFB3 NM_004566.2 5209 5,23 6,16E-26
ILMN_1675947 MT3 NM_005954.2 4504 4,91 6,68E-24
ILMN_1765796 ENO2 NM_001975.2 2026 4,72 4,25E-23
ILMN_2188862 GDF15 NM_004864.1 9518 4,56 9,53E-23
ILMN_1682599 GPRC5A NM_003979.3 9052 4,51 2,67E-25
ILMN_1661599 DDIT4 NM_019058.2 54541 4,48 1,28E-24
ILMN_1758164 STC1 NM_003155.2 6781 4,35 2,08E-24
ILMN_2375879 VEGFA NM_003376.4 7422 4,30 7,69E-22
ILMN_1756417 ANKRD37 NM_181726.2 353322 4,25 1,37E-24
ILMN_2108735 EEF1A2 NM_001958.2 1917 4,24 1,56E-22
ILMN_1653292 PFKFB4 NM_004567.2 5210 4,21 2,12E-23
ILMN_1659027 SLC2A1 NM_006516.1 6513 4,08 1,41E-23
ILMN_1803882 VEGFA NM_001025367.1 7422 4,07 9,09E-23
ILMN_1809931 NDRG1 NM_006096.2 10397 4,06 3,22E-23
ILMN_1843198 4,02 4,25E-23
ILMN_1792356 DPYSL4 NM_006426.1 10570 3,91 5,18E-21
ILMN_1680139 MAFF NM_012323.2 23764 3,87 8,15E-22
ILMN_1651496 HIST1H2BD NM_138720.1 3017 3,85 1,74E-22
ILMN_1744963 ERO1L NM_014584.1 30001 3,84 4,67E-23
ILMN_1691884 STC2 M_003714.2 8614 3,81 1,61E-22
ILMN_1659047 HIST2H2AA3 NM_003516.2 8337 3,78 8,71E-23
ILMN_3242900 HIST2H2AA4 NM_001040874.1 723790 3,75 1,09E-20
ILMN_1767556 C10orf10 NM_007021.2 11067 3,71 1,56E-22
ILMN_1725139 CA9 NM_001216.1 768 3,69 1,68E-22
ILMN_1660847 PFKFB3 NM_004566.2 5209 3,69 1,43E-19
ILMN_1772876 ZNF395 NM_018660.2 55893 3,66 1,99E-22
ILMN_1659990 C7orf68 NM_013332.3 29923 3,65 2,20E-19
ILMN_2144426 HIST2H2AA3 NM_003516 2 8337 3,65 2,14E-19
ILMN_1890614 3,60 1,61E-22
ILMN_1685714 INHBB NM_002193 1 3625 3,60 9,57E-22
ILMN_2386444 ANGPTL4 NM_0010396671 51129 3,59 2,80E-20
ILMN_2413158 PODXL NM_001018111 1 5420 3,57 6,74E-21
ILMN_2361862 VLDLR NM_001018056 1 7436 3,53 1,08E-22
ILMN_3308961 MIR1974 NR_031738 1 1E+08 3,51 9,04E-17
ILMN_1801077 PLIN2 NM_001122 2 123 3,49 1,34E-20
ILMN_1666022 TNFRSF10D NM_003840 3 8793 3,48 2,68E-21
ILMN_1724658 BNIP3 NM_004052 2 664 3,47 4,02E-23
ILMN_1693334 P4HA1 NM_000917 2 5033 3,46 2,01E-19
ILMN_1722532 JMJD1A NM_018433 3 55818 3,45 9,20E-19
ILMN_2138765 PLIN2 NM_00112 2 123 3,41 1,08E-22
ILMN_1764090 AK3L1 NM_203464 1 205 3,40 2,65E-19
ILMN_1768973 HIST2H2AC NM_003517 2 8338 3,39 1,33E-19
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(continued)
Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_1665510 ERRFI1 NM_018948 2 54206 3,36 1.01E-21
ILMN_3181489 LOC100130790 XM_001726820 1 1E+08 3,33 1,29E-21
ILMN_2337058 PORCN NM_022825 2 64840 3,30 9,88E-21
ILMN_1758623 HIST1H2BD M_138720 1 3017 3,29 1,53E-21
ILMN_1809813 PGF NM_002632 4 5228 3,28 5,12E-18
ILMN_1752510 FAM13A NM_001015045 1 10144 3,25 2,44E-19
ILMN_1704446 SLC6A10P NR_003083 2 386757 3,23 4,31E-18
ILMN_1775708 SLC2A3 NM_006931 1 6515 3,23 1,79E-20
ILMN_1798249 AK3L1 NM_203464 1 205 3,18 1,00E-19
ILMN_2186137 RRAD NM_004165 1 6236 3,18 8,49E-19
ILMN_1718866 C5orf46 NM_206966 2 389336 3,15 2,64E-17
ILMN_1699772 RRAGD NM_021244 3 58528 3,13 3,68E-20
ILMN_1779258 LOC644774 XM_927868 1 644774 3,09 7,13E-21
ILMN_1656501 DUSP5 NM_004419 3 1847 3,07 2,80E-20
ILMN_1792455 TMEM158 NM_015444 2 25907 3,06 1,77E-19
ILMN_1673521 KISS1R NM_032551 3 84634 3,05 1,09E-18
ILMN_2322375 MAFF NM_012323 2 23764 3,04 7,32E-17
ILMN_1777513 KCTD11 NM_001002914 2 147040 3,02 9,05E-18
ILMN_2216852 PGK1 NM_000291 2 5230 2,97 8,62E-20
ILMN_1664855 PPP1R14C NM_030949 2 81706 2,96 7,35E-20
ILMN_1798360 CXCR7 NM_020311 2 57007 2,96 2,20E-19
ILMN_1794017 SERTAD1 NM_013376 3 29950 2,93 4,26E-18
ILMN_2150856 SERPINB2 NM_002575 1 5055 2,92 6,83E-19
ILMN_1723486 HK2 NM_000189 4 3099 2,90 2,39E-18
ILMN_3267451 GAPDHL6 XM_001726954 1 729403 2,90 5,90E-19
ILMN_2225537 PTGR1 NM_012212 2 22949 2,90 3,44E-19
ILMN_1718961 BNIP3L NM_004331 2 665 2,88 1,42E-18
ILMN_1794863 CAMK2N1 NM_018584 5 55450 2,88 1,28E-16
ILMN_2308903 WFDC3 NM_181522 1 140686 2,87 6,22E-19
ILMN_1751120 HIST1H4H NM_003543 3 8365 2,86 9,37E-19
ILMN_1755749 PGK1 NM_000291 2 5230 2,85 2,91E-18
ILMN_2401258 FAM13A NM_014883 2 10144 2,84 1,23E-18
ILMN_1733110 RASSF7 NM_003475 2 8045 2,83 1,99E-18
ILMN_1755974 ALDOC NM_005165 230 2,83 2,27E-19
ILMN_1707342 LRIG1 NM_015541 2 26018 2,82 2,37E-19
ILMN_1800512 HMOX1 NM_002133 1 3162 2,82 2,90E-19
ILMN_1784300 TUBA4A NM_006000 1 7277 2,80 1,09E-16
ILMN_1770228 KRT34 NM_021013 3 3885 2,77 2,38E-19
ILMN_1683179 RRAD NM_004165 1 6236 2,75 1,28E-16
ILMN_1717056 TXNRD 1 NM_001093771 1 7296 2,75 1,82E-19
ILMN_3237270 LOC100133609 XM_001720815 1 1E+08 2,75 1,14E-16
ILMN_1692938 PSAT1 NM_021154 3 29968 2,74 1,24E-19
ILMN_3283772 LOC644237 XR_039184 1 644237 2,73 5,88E-18
ILMN_2150851 SERPINB2 NM_002575 1 5055 2,73 8,07E-16
ILMN_1671478 CKB NM_0018233 1152 2,73 1,66E-17
ILMN_1749892 EGLN1 NM_022051 1 54583 2,72 5,54E-20
ILMN_1679727 CLK1 NM_0040712 1195 2,72 7,69E-18
EP 2 607 478 A1
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(continued)
Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_1795963 OKL38 NM_013370 2 29948 2,72 4,16E-16
ILMN_1667791 PPFIA4 NM_015053 1 8497 2,71 2,82E-18
ILMN_2128795 LRIG1 NM_015541 2 26018 2,70 1,92E-19
ILMN_1720373 SLC7A5 NM_003486 5 8140 2,69 3,12E-18
ILMN_1789702 GBE1 NM_000158 2 2632 2,68 7,33E-19
ILMN_1774390 LOC441054 XM_498987 2 441054 2,68 3,51E-17
ILMN_2227248 SLAMF9 NM_033438 1 89886 2,67 4,76E-15
ILMN_1660654 CDCA2 NM_152562 2 157313 2,66 9,49E-19
ILMN_1659936 PPP1R15A NM_014330 2 23645 2,65 1,65E-19
ILMN_1682717 IER3 NM_003897 3 8870 2,62 6,46E-17
ILMN_2338038 AK3L1 NM_013410 2 205 2,61 1,40E-18
ILMN_2382942 CA12 NM_001218 3 771 2,61 6,22E-19
ILMN_1862909 2,60 8,29E-17
ILMN_2133187 POL3S NM_001039503 2 339105 2,59 1,93E-15
ILMN_2054297 PTGS2 NM_000963 1 5743 2,59 2,39E-18
ILMN_1756992 MUC1 NM_001044391 1 4582 2,56 3,78E-17
ILMN_1704531 PTGR1 NM_012212 2 22949 2,56 3,30E-18
ILMN_2371458 CXCR7 NM_001047841 1 57007 2,54 3,01E-16
ILMN_1692785 KLHL21 NM_014851 2 9903 2,54 1,29E-17
ILMN_1699265 TNFRSF10B NM_0038423 8795 2,54 2,63E-15
ILMN_1703330 FEM1C NM_020177 2 56929 2,53 8,04E-19
ILMN_1703123 AXUD1 NM_033027 2 6465 1 2,51 1,01E-16
ILMN_1674376 ANGPTL4 NM_139314 1 51129 2,49 4,00E-14
ILMN_1708934 ADM NM_001124 1 133 2,48 2,04E-17
ILMN_1739942 FAM117B NM_173511 2 150864 2,48 4,26E-16
ILMN_2173451 GPI NM_000175 2 2821 2,47 9,81E-17
ILMN_2404135 RIOK3 NM_003831 2 8780 2,47 4,27E-17
ILMN_1714741 LOC346887 XM_943533 1 346887 2,46 5,70E-18
ILMN_1777499 LOC731007 XM_001132080 1 731007 2,46 1,84E-17
ILMN_1790778 PNMA2 NM_007257 4 10687 2,46 7,49E-16
ILMN_1806349 SLC6A8 NM_005629 1 6535 2,45 2,54E-15
ILMN_1749838 MZF1 NM_198055 1 7593 2,45 4,11E-16
ILMN_1797372 C3orf58 NM_173552 2 205428 2,45 4,19E-17
ILMN_3233930 LOC390557 XM_001726973 1 390557 2,45 2,17E-16
ILMN_1758672 FAM107B NM_031453 2 83641 2,44 1,94E-17
ILMN_1736670 PPP1R3C NM_005398 4 5507 2,44 5,46E-17
ILMN_1694810 PANX2 NM_052839 2 56666 2,42 6,46E-17
ILMN_1750912 STXBP6 NM_014178 6 29091 2,42 1,15E-17
ILMN_1813314 HIST1H2BK NM_080593 1 85236 2,41 2,26E-16
ILMN_1720998 CA12 NM_001218 3 771 2,41 4,27E-17
ILMN_1674243 TFRC NM_003234 1 7037 2,40 2,90E-18
ILMN_1724700 RIOK3 NM_003831 3 8780 2,40 3,19E-18
ILMN_1773407 C16orf72 NM_014117 2 29035 2,40 5,78E-17
ILMN_2374865 ATF3 NM_001040619 1 467 2,39 8,20E-15
ILMN_1655796 Mar-03 XM_001127871 1 115123 2,37 6,13E-17
ILMN_1672350 JAM2 NM_021219 2 58494 2,37 3,43E-16
ILMN_2380163 PTPRF NM_002840 3 5792 2,36 1,57E-16
EP 2 607 478 A1
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(continued)
Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_1775743 BTG1 NM_001731 1 694 2,36 4,15E-16
ILMN_1803647 FAM162A NM_014367 3 26355 2,36 8,92E-14
ILMN_2132982 IGFBP5 NM_000599 2 3488 2,36 1,60E-15
ILMN_1750324 IGFBP5 NM_000599 2 3488 2,34 2,44E-16
ILMN_3245418 FAM180A NM_205855 2 389558 2,34 4,24E-17
ILMN 2045419 BNIP3L NM_004331 2 665 2,33 2,83E-16
ILMN_1668861 LOC732165 XM_001134259 1 732165 2,33 6,90E-16
ILMN_3280402 LOC100132510 XM_001725190 1 1E+08 2,32 4,67E-13
ILMN_1805737 PFKP NM_002627 3 5214 2,32 6,18E-18
ILMN_1804822 SRXN1 NM_080725 1 140809 2,32 2,36E-16
ILMN_2324421 TXNRD1 NM_182743 1 7296 2,30 4,11E-16
ILMN_2103547 GOLGA8B NM_001023567 2 440270 2,29 7,60E-15
ILMN_1815023 PIM1 NM_002648 2 5292 2,29 2,51E-16
ILMN_2364022 SLC16A3 NM_004207 2 9123 2,29 3,30E-15
ILMN_1775380 SMOX NM_175842 1 54498 2,29 8,13E-16
ILMN_1741148 ALDOA NM_184043 1 226 2,28 1,28E-16
ILMN_2381697 P4HA2 NM_001017974 1 8974 2,27 2,28E-16
ILMN_2371911 MUC1 M_001044390 1 4582 2,27 3,97E-15
ILMN_3237448 BEND5 NM_024603 2 79656 2,26 6,24E-16
ILMN_3228688 LOC730415 XM_001720835 1 730415 2,25 8,25E-17
ILMN_3237511 C4orf47 NM_001114357 1 441054 2,24 8,23E-16
ILMN_1726456 SLC3A2 NM_001013251 1 6520 2,24 2,80E-16
ILMN_1815121 PLAGL1 NM_001080951 1 5325 2,24 8,26E-17
ILMN_1752226 P2RY11 NM_002566 4 5032 2,23 9,51E-16
ILMN_1796179 HIST1H2BK NM_080593 1 85236 2,23 1,80E-15
ILMN_1676899 YEATS2 NM_018023 3 55689 2,21 3,58E-16
ILMN_1699644 Mar-03 XM_001127871 1 115123 2,20 1,32E-14
ILMN 3188106 CYTH2 NM_017457 4 9266 2,19 4,76E-16
ILMN_1684158 GPT2 NM_133443 1 84706 2,19 1,57E-16
ILMN_1751228 C20orf46 NM_018354 1 55321 2,17 6,13E-15
ILMN_1676629 INSIG2 NM_016133 2 51141 2,16 7,69E-16
ILMN_1671731 AVPI1 NM_021732 1 60370 2,16 4,35E-16
ILMN_1738742 PLAT NM_000930 2 5327 2,16 2,54E-16
ILMN_1801313 SIAH2 NM_005067 5 6478 2,15 4,06E-15
ILMN_1679041 SLC3A2 NM_001013251 1 6520 2,15 7,21E-14
ILMN_1748883 CDKN2D NM_0794212 1032 2,14 6,70E-16
ILMN_1677511 PTGS2 NM_0009631 5743 2,13 6,45E-13
ILMN_2322498 RORA NM_0029432 6095 2,13 1,04E-13
ILMN_3305475 LOC729708 XM_0017257001 729708 2,12 8,75E-16
ILMN_1764177 JARID2 NM_0049732 3720 2,12 6,46E-17
ILMN_2342066 METRNL NM_001004431 1 284207 2,12 5,35E-15
ILMN_1694240 MAP2K1 NM_002755 2 5604 2,11 2,41E-15
ILMN_1653466 HES4 NM_021170 2 57801 2,11 2,65E-14
ILMN_1792689 HIST1H2AC NM_003512 3 8334 2,10 6,88E-16
ILMN_1810560 P8 NM_012385 1 26471 2,09 4,50E-13
ILMN_2358069 MAD1L1 NM_001013836 1 8379 2,09 2,64E-13
ILMN_1684114 LOC286016 NR_002187 2 286016 2,09 1,09E-16
EP 2 607 478 A1
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(continued)
Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_1689274 NIPA1 NM_144599 3 123606 2,08 2,54E-14
ILMN_1662619 TFPI NM_006287 4 7035 2,06 1,04E-16
ILMN_1789991 Mar-04 NM_020814 1 57574 2,06 5,90E-16
ILMN_3237966 FBXL11 NM_012308 1 22992 2,06 6,19E-15
ILMN_1716608 NGF NM_002506 2 4803 2,06 2,25E-15
ILMN_1732612 SHB NM_003028 2 6461 2,06 2,28E-14
ILMN_1716733 MYOM2 NM_003970 1 9172 2,05 1,78E-14
ILMN_2405305 ARNTL NM_001030272 1 406 2,05 2,86E-15
ILMN_2367258 SMOX NM_175840 1 54498 2,05 1,99E-14
ILMN_1758626 IDS NM_000202 3 3423 2,05 2,59E-16
ILMN_1801156 RLF NM_012421 2 6018 2,05 1,34E-13
ILMN_1757877 HCFC1R1 NM_001002018 1 54985 2,05 4,32E-17
ILMN_1667432 HYAL3 NM_003549 2 8372 2,05 3,41E-15
ILMN_1679428 CHIC2 NM_012110 2 26511 2,04 1,45E-16
ILMN_3291053 LOC346085 XR_019389 1 346085 2,04 1,27E-13
ILMN_2390974 DNAJB2 NM_006736 5 3300 2,04 1,28E-16
ILMN_1707124 TFPI NM_006287 4 7035 2,04 8,73E-16
ILMN_1801610 METRNL XM_941466 2 284207 2,03 3,56E-12
ILMN_1686750 MGEA5 NM_012215 2 10724 2,03 4,49E-15
ILMN_1786139 VKORC1 NM_024006 4 79001 2,02 1,08E-12
ILMN_1816244 2,02 1,74E-15
ILMN_1723412 ASCL2 NM_005170 2 430 2,02 3,54E-13
ILMN_1658110 C18orf19 NM_152352 1 125228 2,02 4,22E-16
ILMN_2374340 PLAUR NM_001005376 1 5329 2,01 3,62E-15
ILMN_2174612 CNOT8 NM_004779 4 9337 2,01 3,11E-14
ILMN_1827736 2,01 1,75E-14
ILMN_2408543 PLAUR NM_002659 2 5329 2,01 4,47E-15
ILMN_1655930 ELL2 NM_012081 4 22936 2,00 6,97E-13
ILMN_2129505 CYBASC3 NM_153611 3 220002 -2,00 2,85E-15
ILMN_1747016 CEP55 NM_018131 3 55165 -2,01 8,25E-16
ILMN_1777325 STAT1 NM_007315 2 6772 -2,01 5,16E-15
ILMN_1666545 GCNT1 NM_001097635 1 2650 -2,01 8,75E-15
ILMN_2157240 MNS1 NM_018365 1 55329 -2,02 7,34E-16
ILMN_1657962 LOC728946 XM_001128870 1 728946 -2,02 2,32E-12
ILMN_1661346 LOC648210 XR_018923 1 648210 -2,02 1,42E-15
ILMN_1725241 GSTK1 NM_015917 1 373156 -2,02 1,28E-16
ILMN_3212373 LOC727803 XR_039632 1 727803 -2,02 2,10E-14
ILMN_1699980 TSPAN18 NM_130783 3 90139 -2,03 5,59E-14
ILMN_1731966 LEPR NM_001003679 1 3953 -2,03 1,60E-16
ILMN_1669584 ILF3 NM_004516 2 3609 -2,03 4,72E-14
ILMN_1708672 ACAT2 NM_005891 2 39 -2,03 1,04E-14
ILMN_1741200 RFX5 NM_001025603 1 5993 -2,04 3,45E-14
ILMN_1690105 STAT1 NM_007315 2 6772 -2,04 3,31E-15
ILMN_1681283 HIF1A NM_001530 2 3091 -2,05 4,81E-13
ILMN_1802654 GLT8D2 NM_031302 3 83468 -2,05 1,98E-16
ILMN_2212909 MELK NM_014791 2 9833 -2,05 5,49E-15
ILMN_1764764 MUM1 NM_032853 2 84939 -2,05 9,86E-15
EP 2 607 478 A1
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(continued)
Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_3305949 LOC730246 XR_016080 2 730246 -2,06 6,16E-16
ILMN_1668345 OAF NM_178507 2 220323 -2,06 1,94E-13
ILMN_1684554 COL16A1 NM_001856 3 1307 -2,06 1,11E-13
ILMN_1794132 NDUFS8 NM_002496 1 4728 -2,07 1,96E-15
ILMN_1687751 BAALC NM_001024372 1 79870 -2,07 1,98E-15
ILMN_1769158 ISOC2 NM_024710 1 79763 -2,08 2,20E-13
ILMN_1709043 C9orf46 NM_018465 2 55848 -2,08 7,52E-17
ILMN_1729288 C1QTNF6 NM_031910 3 114904 -2,08 8,25E-16
ILMN_1696601 VARS NM_006295 2 7407 -2,08 4,76E-16
ILMN_1651958 MGP NM_000900 2 4256 -2,09 4,22E-16
ILMN_2324002 CALD1 NM_033157 2 800 -2,11 4,48E-16
ILMN_1713499 WISP1 NM_003882 2 8840 -2,11 6,51E-16
ILMN_1675062 MYL9 NM_006097 3 10398 -2,11 2,40E-15
ILMN_1667692 PTGIS NM_000961 3 5740 -2,11 3,53E-14
ILMN_2332553 MSRB3 NM_198080 2 253827 -2,12 5,02E-16
ILMN_1815626 DHCR7 NM_001360 1 1717 -2,12 7,45E-15
ILMN_1810628 KIAA0367 NM_015225 1 23273 -2,12 2,23E-16
ILMN_1696537 DDIT4L NM_145244 2 115265 -2,12 1,35E-13
ILMN_1712684 FAM20C NM_020223 2 56975 -2,12 2,78E-14
ILMN_1716552 ENAH NM_018212 4 55740 -2,13 4,35E-16
ILMN_1726589 CD248 NM_020404 2 57124 -2,13 4,94E-16
ILMN_1806037 TK1 NM_003258 2 7083 -2,14 1,43E-11
ILMN_2380771 AKR1A1 NM_153326 1 10327 -2,14 9,40E-18
ILMN_1723912 IFI44L NM_006820 1 10964 -2,15 3,35E-15
ILMN_1761941 C4orf18 NM_016613 5 51313 -2,15 4,78E-15
ILMN_1708486 CNN2 NM_004368 2 1265 -2,15 1,15E-14
ILMN_1714730 UBE2C NM_181803 1 11065 -2,16 4,76E-16
ILMN_1815859 ERCC2 NM_000400 2 2068 -2,17 4,72E-14
ILMN_1738552 SLC1A3 NM_004172 3 6507 -2,18 1,81E-15
ILMN_1811909 LOC402221 XM_938988 1 402221 -2,18 1,40E-16
ILMN_1706498 DSE NM_013352 2 29940 -2,19 7,33E-17
ILMN_2173611 MT1E NM_175617 3 4493 -2,20 7,30E-16
ILMN_1797728 HMGCS1 NM_002130 6 3157 -2,20 1,26E-13
ILMN_1814998 FKSG30 NM_001017421 1 440915 -2,20 3,22E-16
ILMN_2301083 UBE2C NM_181800 1 11065 -2,20 4,47E-16
ILMN_1729117 COL5A2 NM_000393 3 1290 -2,21 2,38E-16
ILMN_1728047 AKR1A1 NM_006066 2 10327 -2,21 1,70E-17
ILMN_2053415 LDLR NM_000527 2 3949 -2,22 4,17E-16
ILMN_1800091 RARRES1 NM_206963 1 5918 -2,22 4,11E-16
ILMN_2062701 GAS1 NM_002048 1 2619 -2,22 2,40E-16
ILMN_1772644 EML3 NM_153265 2 256364 -2,23 1,49E-14
ILMN_1678842 THBS2 NM_003247 2 7058 -2,24 3,88E-17
ILMN_3239771 DLGAP5 NM_014750 3 9787 -2,24 6,08E-15
ILMN_1690921 STAT2 NM_005419 2 6773 -2,24 2,41E-17
ILMN_1747195 PSMB8 NM_148919 3 5696 -2,24 2,82E-15
ILMN_1704154 TNFRSF19 NM_148957 2 55504 -2,24 6,19E-16
ILMN_2379788 HIF1A NM_181054 1 3091 -2,24 3,20E-15
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Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_1790461 C6orf125 NM_032340 2 84300 -2,25 2,04E-16
ILMN_1786065 UHRF1 NM_001048201 1 29128 -2,25 1,15E-15
ILMN_1776953 MYL9 NM_006097 3 10398 -2,25 3,27E-13
ILMN_1796471 GDF5 NM_000557 2 8200 -2,25 3,62E-15
ILMN_2344283 FMO3 NM_001002294 1 2328 -2,27 2,76E-15
ILMN_2360710 TPM1 NM_001018004 1 7168 -2,27 8,93E-17
ILMN_1716687 TPM1 NM_001018020 1 7168 -2,28 2,60E-16
ILMN_1759598 DLX5 NM_005221 5 1749 -2,28 1,52E-17
ILMN_1787981 MFAP2 NM_017459 1 4237 -2,29 9,04E-17
ILMN_2390919 FBLN2 NM_001998 2 2199 -2,30 3,99E-17
ILMN_1711439 EMILIN1 NM_007046 1 11117 -2,30 2,48E-13
ILMN_1699651 IL6 NM_000600 1 3569 -2,31 6,37E-16
ILMN_1854469 -2,31 6,40E-18
ILMN_2390338 UBE2E3 NM_006357 2 10477 -2,31 1,14E-15
ILMN_1798654 MCM6 NM_005915 4 4175 -2,31 1,18E-17
ILMN_1790689 CRISPLD2 NM_031476 2 83716 -2,32 2,00E-16
ILMN_1657796 STMN1 NM_203401 1 3925 -2,32 1,62E-15
ILMN_1703558 FHL3 NM_004468 3 2275 -2,34 1,69E-14
ILMN_1812091 FAM20A NM_017565 2 54757 -2,34 3,43E-16
ILMN_3247132 LOC730743 XM_001127014 1 730743 -2,35 6,35E-15
ILMN_1685441 ASAP3 NM_017707 2 55616 -2,35 1,09E-16
ILMN_1657683 C1orf198 NM_032800 1 84886 -2,35 1,61E-17
ILMN_1701441 LPAR1 NM_057159 2 1902 -2,35 6,46E-17
ILMN_1739496 PRRX1 NM_006902 3 5396 -2,36 6,73E-18
ILMN_1666305 CDKN3 NM_005192 2 1033 -2,37 4,47E-16
ILMN_1741356 PRICKLE1 NM_153026 1 144165 -2,37 1,49E-16
ILMN_1803825 CXCL12 NM_000609 4 6387 -2,38 3,81E-15
ILMN_1687301 VCAN NM_004385 2 1462 -2,38 6,18E-18
ILMN_1800697 LDB2 NM_001290 2 9079 -2,38 2,41E-17
ILMN_1774602 FBLN2 NM_001998 2 2199 -2,40 1,42E-16
ILMN_2390299 PSMB8 NM_004159 4 5696 -2,40 1,67E-14
ILMN_1680738 C5orf13 NM_004772 1 9315 -2,41 2,07E-17
ILMN_2229877 PCDH18 NM_019035 2 54510 -2,41 2,08E-16
ILMN_1794501 HAS3 NM_005329 2 3038 -2,42 2,78E-16
ILMN_1676088 MSRB3 NM_198080 2 253827 -2,43 2,48E-17
ILMN_1756572 COQ2 NM_015697 6 27235 -2,49 9,32E-17
ILMN_1785891 PRKD1 NM_002742 2 5587 -2,51 2,07E-17
ILMN_1728934 PRC1 NM_199413 1 9055 -2,53 3,96E-18
ILMN_1733094 STEAP1 NM_012449 2 26872 -2,54 1,18E-17
ILMN_1663390 CDC20 NM_001255 2 991 -2,55 5,35E-16
ILMN_1669119 LOC728946 XM_001128870 1 728946 -2,56 2,21E-17
ILMN_1740407 CHSY3 NM_175856 4 337876 -2,57 9,91E-17
ILMN_1805561 SLC14A1 NM_015865 2 6563 -2,57 7,55E-18
ILMN_1690125 PDLIM7 NM_213636 1 9260 -2,57 7,11E-16
ILMN_1744487 C1QTNF5 NM_015645 2 114902 -2,59 9,47E-18
ILMN_1700268 QPRT NM_014298 3 23475 -2,59 1,28E-16
ILMN_1667893 TNS3 NM_022748 10 64759 -2,61 1,07E-17
EP 2 607 478 A1
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(continued)
Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_1715508 NNMT NM_006169 2 4837 -2,62 8,14E-20
ILMN_1786612 PSME2 NM_002818 2 5721 -2,64 4,12E-18
ILMN_1801939 CCNB2 NM_004701 2 9133 -2,66 6,59E-16
ILMN_1754969 LMCD1 NM_014583 2 29995 -2,67 2,57E-20
ILMN_1719392 FH NM_000143 2 2271 -2,67 4,48E-16
ILMN_2110252 NPM3 NM_006993 1 10360 -2,68 6,88E-19
ILMN_2349459 BIRC5 NM-001168 2 332 -2,71 2,96E-17
ILMN_1678493 CHN1 NM_001025201 1 1123 -2,73 8,62E-20
ILMN_1663575 MGC87042 XM_001128032 1 256227 -2,77 2,77E-18
ILMN_2148785 GBP1 NM_002053 1 2633 -2,77 3,09E-17
ILMN_1691364 STAT1 NM_139266 1 6772 -2,77 1,53E-18
ILMN_1765990 KCNK2 NM_001017425 2 3776 -2,82 3,12E-18
ILMN_1763260 HIF1A NM_001530 2 3091 -2,83 4,42E-19
ILMN_1808657 FMO3 NM_006894 4 2328 -2,85 1,15E-17
ILMN_2234956 LEPR NM_001003679 1 3953 -2,85 4,08E-18
ILMN_1702363 SULF1 M_015170 1 23213 -2,90 8,61E-19
ILMN_1790338 PRRX2 NM_016307 3 51450 -2,93 2,27E-19
ILMN_2388547 EPSTI1 NM_033255 2 94240 -2,93 3,21E-18
ILMN_1772612 ANGPTL2 NM_012098 2 23452 -2,93 6,80E-20
ILMN_1725090 CTHRC1 NM_138455 2 115908 -2,95 1,19E-19
ILMN_2145670 TNC NM_002160 1 3371 -2,96 1,28E-16
ILMN_1705750 TGM2 NM_004613 2 7052 -2,98 1,33E-19
ILMN_1765701 LOC399942 XM_934471 1 399942 -2,98 2,89E-18
ILMN_1686116 THBS1 NM_003246 2 7057 -3,00 2,94E-20
ILMN_1765557 OLFML2B NM_015441 1 25903 -3,04 3,54E-19
ILMN_1676663 TNFRSF11B NM_002546 3 4982 -3,04 5,10E-20
ILMN_1810836 PDE5A NM_001083 3 8654 -3,04 2,23E-19
ILMN_1671703 ACTA2 NM_001613 1 59 -3,04 1,49E-19
ILMN_1686097 TOP2A NM_001067 2 7153 -3,07 1,22E-17
ILMN_1719759 TNC NM_002160 2 3371 -3,17 2,91E-19
ILMN_1727532 OLFML3 NM_020190 2 56944 -3,25 5,52E-21
ILMN_1695658 KIF20A NM_005733 1 10112 -3,25 1,02E-20
ILMN_2376953 KCNK2 NM_001017425 2 3776 -3,27 1,54E-19
ILMN_2285996 KIAA0101 NM_014736 4 9768 -3,27 3,14E-19
ILMN_1691476 MYLK NM_053032 2 4638 -3,27 7,42E-20
ILMN_1770290 CNN2 NM_201277 1 1265 -3,30 1,64E-22
ILMN_2400935 TAGLN NM_003186 3 6876 -3,44 1,23E-20
ILMN_1689111 CXCL12 NM_000609 4 6387 -3,44 5,78E-20
ILMN_1784948 SPOCD1 NM_144569 4 90853 -3,46 1,08E-22
ILMN_1790529 LUM NM_002345 3 4060 -3,46 7,69E-22
ILMN_1791447 CXCL12 NM_199168 2 6387 -3,48 3,19E-20
ILMN_1789507 COL11A1 NM_001854 3 1301 -3,53 3,22E-20
ILMN_2150894 ALDH1B1 NM_000692 3 219 -3,56 3,80E-20
ILMN_2117508 CTHRC1 NM_138455 2 115908 -3,58 1,82E-19
ILMN_1772910 GAS1 NM_002048 1 2619 -3,75 2,27E-18
ILMN_1689088 COLEC12 NM_130386 1 81035 -3,75 5,67E-22
ILMN_1656057 PLAU NM_002658 2 5328 -3,95 1,77E-21
EP 2 607 478 A1
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(continued)
Table 2A PHE vs BAS filtered
ProbeID GeneName Refseq Entrez
logFC(D142_PHE - 
D142_BAS)
adj.P.Val
(D142_PHE - 
D142_BAS)
ILMN_1733756 COL12A1 NM_080645 2 1303 -3,95 9,88E-21
ILMN_1813704 KIAA1199 NM_018689 1 57214 -4,06 1,56E-22
ILMN_2234697 BEX1 NM_018476 3 55859 -4,70 1,94E-25
ILMN_1738116 TMEM119 NM_181724 1 338773 -4,96 1,29E-25
ILMN_2307903 VCAM1 NM_001078 2 7412 -5,09 4,72E-26
Table 2B DFO versus Bas filtered
ProbeID GeneName Refseq Entrez logFC(D142_ DFO - 
D142_BAS)
adj P Val(D142_D 
FO - D142_BAS)
ILMN_2188862 GDF15 NM_004864 1 9518 6,31 3,83E-26
ILMN_1707727 ANGPTL4 NM_139314 1 51129 6,19 3,83E-26
ILMN_1756573 NDUFA4L2 NM_020142 3 56901 5,66 2,14E-25
ILMN_1784294 CPA4 NM_016352 2 51200 5,59 2,42E-27
ILMN_1661599 DDIT4 NM_019058 2 54541 4,37 5,98E-24
ILMN_1765796 ENO2 NM_001975 2 2026 4,08 3,37E-21
ILMN_2186061 PFKFB3 NM_004566 2 5209 4,03 1,00E-22
ILMN_1692938 PSAT1 NM_021154 3 29968 3,93 3,00E-23
ILMN_1676984 DDIT3 NM_004083 4 1649 3,92 2,89E-19
ILMN_1770228 KRT34 NM_021013 3 3885 3,81 1,84E-22
ILMN_1758164 STC1 NM_003155 2 6781 3,77 1,84E-22
ILMN_1744963 ERO1L NM_014584 1 30001 3,58 6,82E-22
ILMN_1809931 NDRG1 NM_006096 2 10397 3,57 1,62E-21
ILMN_1691884 STC2 NM_003714 2 8614 3,54 2,78E-21
ILMN_1653292 PFKFB4 NM_004567 2 5210 3,53 3,37E-21
ILMN_1659027 SLC2A1 NM_006516 1 6513 3,46 1,83E-21
ILMN_1890614 3,41 1,62E-21
ILMN_2375879 VEGFA NM_003376 4 7422 3,40 7,41E-19
ILMN_1756417 ANKRD37 NM_181726 2 353322 3,40 1,07E-21
ILMN_1724658 BNIP3 NM_004052 2 664 3,37 1,84E-22
ILMN_1651496 HIST1H2BD NM_138720 1 3017 3,33 1,78E-20
ILMN_1725139 CA9 NM_001216 1 768 3,31 6,72E-21
ILMN_1843198 3,25 1,78E-20
ILMN_1693334 P4HA1 NM_000917 2 5033 3,24 2,45E-18
ILMN_2374865 ATF3 NM_001040619 1 467 3,23 8,76E-18
ILMN_1720373 SLC7A5 NM_003486 5 8140 3,21 7,53E-20
ILMN_2361862 VLDLR NM_001018056 1 7436 3,17 3,63E-21
ILMN_1787815 TRIB3 NM_021158 3 57761 3,16 3,87E-19
ILMN_1767556 C10orf10 NM_007021 2 11067 3,15 2,12E-20
ILMN_1803882 VEGFA NM_001025367 1 7422 3,15 1,36E-19
ILMN_3305273 LOC729779 XR_019592 2 729779 3,12 4,39E-20
ILMN_2186137 RRAD NM_004165 1 6236 3,12 3,17E-18
ILMN_2150851 SERPINB2 NM_002575 1 5055 3,06 8,95E-17
ILMN_1792356 DPYSL4 NM_006426 1 10570 3,05 6,25E-18
ILMN_1659990 C7orf68 NM_013332 3 29923 3,04 4,76E-17
ILMN_2150856 SERPINB2 NM_002575 1 5055 3,04 5,71E-19
ILMN_1675947 MT3 NM_005954 2 4504 3,00 3,99E-18
ILMN_1664855 PPP1R14C NM_030949 2 81706 2,96 1,53E-19
EP 2 607 478 A1
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(continued)
Table 2B DFO versus Bas filtered
ProbeID GeneName Refseq Entrez logFC(D142_ DFO - 
D142_BAS)
adj P Val(D142_D 
FO - D142_BAS)
ILMN_1801077 PLIN2 NM_001122 2 123 2,94 2,48E-18
ILMN_1796417 ASNS NM_133436 1 440 2,93 1,50E-20
ILMN_2413158 PODXL NM_001018111 1 5420 2,92 2,48E-18
ILMN_1660067 LOC728285 XM_001127070 1 728285 2,89 1,99E-17
ILMN_1810725 FAM129A NM_052966 2 116496 2,88 6,71E-18
ILMN_2405521 MTHFD2 NM_001040409 1 10797 2,84 2,89E-19
ILMN_1683179 RRAD NM_004165 1 6236 2,83 1,24E-16
ILMN_1704446 SLC6A10P NR_003083 2 386757 2,82 2,91E-16
ILMN_1773337 DKK1 NM_012242 2 22943 2,79 2,73E-18
ILMN_1674706 MTHFD2 NM_006636 3 10797 2,79 8,64E-17
ILMN_1787212 CDKN1A NM_078467 1 1026 2,78 2,98E-17
ILMN_1772876 ZNF395 NM_018660 2 55893 2,75 7,85E-19
ILMN_2216852 PGK1 NM_000291 2 5230 2,75 1,24E-18
ILMN_1764090 AK3L1 NM_203464 1 205 2,74 1,29E-16
ILMN_1699265 TNFRSF10B NM_003842 3 8795 2,74 7,76E-16
ILMN_2138765 PLIN2 NM_001122 2 123 2,74 6,75E-20
ILMN_1716608 NGF NM_002506 2 4803 2,73 4,01E-18
ILMN_2108735 EEF1A2 NM_001958 2 1917 2,72 2,98E-17
ILMN_1750324 IGFBP5 NM_000599 2 3488 2,71 1,16E-17
ILMN_1658448 KRTAP2-1 XM_926554 2 81872 2,71 5,98E-16
ILMN_1667966 C1orf24 NM_052966 1 116496 2,70 2,84E-17
ILMN_2337058 PORCN NM_022825 2 64840 2,69 3,64E-18
ILMN_1798249 AK3L1 NM_203464 1 205 2,66 1,87E-17
ILMN_1714108 TP53INP1 NM_033285 2 94241 2,66 4,41E-17
ILMN_1794863 CAMK2N1 NM_018584 5 55450 2,65 2,11E-15
ILMN_2386444 ANGPTL4 NM_001039667 1 51129 2,64 1,24E-16
ILMN_1694075 GADD45A NM_001924 2 1647 2,63 5,15E-18
ILMN_2214197 TP53INP1 NM_033285 2 94241 2,62 1,26E-15
ILMN_3237448 BEND5 NM_024603 2 79656 2,61 3,11E-17
ILMN_1779258 LOC644774 XM_927868 1 644774 2,61 1,13E-18
ILMN_2052208 GADD45A NM_001924 2 1647 2,60 1,87E-17
ILMN_3248701 LOC644350 XM_927511 3 644350 2,60 2,64E-15
ILMN_1718866 C5orf46 NM_206966 2 389336 2,59 7,05E-15
ILMN_1792455 TMEM158 NM_015444 2 25907 2,58 2,84E-17
ILMN_1770085 BTG2 NM_006763 2 7832 2,57 1,07E-17
ILMN_1809813 PGF NM_002632 4 5228 2,55 6,02E-15
ILMN_1665510 ERRFI1 NM_018948 2 54206 2,53 3,47E-18
ILMN_2132982 IGFBP5 NM_000599 2 3488 2,53 5,68E-16
ILMN_1775708 SLC2A3 NM_006931 1 6515 2,53 1,87E-17
ILMN_1699644 Mar-03 XM_001127871 1 115123 2,52 8,86E-16
ILMN_1892403 SNORD13 NR_003041 1 692084 2,51 1,45E-14
ILMN_1803647 FAM162A NM_014367 3 26355 2,50 4,37E-14
ILMN_3237270 LOC100133609 XM_001720815 1 1E+08 2,49 2,64E-15
ILMN_1660847 PFKFB3 NM_004566 2 5209 2,48 6,31E-15
ILMN_1680139 MAFF NM_012323 2 23764 2,48 1,58E-16
ILMN_3248758 LOC728934 XM_001128836 2 728934 2,47 3,31E-15
ILMN_1655796 Mar-03 XM_001127871 1 115123 2,46 4,43E-17
ILMN_2347068 MKNK2 NM_017572 2 2872 2,45 2,57E-15
EP 2 607 478 A1
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(continued)
Table 2B DFO versus Bas filtered
ProbeID GeneName Refseq Entrez logFC(D142_ DFO - 
D142_BAS)
adj P Val(D142_D 
FO - D142_BAS)
ILMN_2387385 IGFBP1 NM_001013029 1 3484 2,45 7,38E-18
ILMN_1699772 RRAGD NM_021244 3 58528 2,43 4,57E-17
ILMN_1758623 HIST1H2BD NM_138720 1 3017 2,40 1,07E-17
ILMN_1682599 GPRC5A NM_003979 3 9052 2,35 1,07E-17
ILMN_1743199 EGR2 NM_000399 2 1959 2,34 3,79E-14
ILMN_1755974 ALDOC NM_005165 2 230 2,33 6,34E-17
ILMN_1736670 PPP1R3C NM_005398 4 5507 2,33 3,28E-16
ILMN_1726456 SLC3A2 NM_001013251 1 6520 2,31 2,77E-16
ILMN_1674243 TFRC NM_003234 1 7037 2,31 1,70E-17
ILMN_1789702 GBE1 NM_000158 2 2632 2,29 8,34E-17
ILMN_2338038 AK3L1 NM_0134102 2 205 2,28 8,93E-17
ILMN_1798081 PTPRF NM_130440 1 5792 2,28 1,53E-13
ILMN_1749892 EGLN1 NM_022051 1 54583 2,28 1,02E-17
ILMN_1679041 SLC3A2 NM_001013251 1 6520 2,26 4,09E-14
ILMN_1794017 SERTAD1 NM_013376 3 29950 2,25 6,43E-15
ILMN_2054297 PTGS2 NM_000963 1 5743 2,25 1,58E-16
ILMN_1718961 BNIP3L NM_004331 2 665 2,24 1,73E-15
ILMN 2113490 NTN4 NM_021229 3 59277 2,23 7,70E-15
ILMN_1795697 PTP4A2 XM_944907 1 8073 2,22 6,02E-15
ILMN_1723486 HK2 NM_000189 4 3099 2,21 4,62E-15
ILMN_1758672 FAM107B NM_031453 2 83641 2,18 7,10E-16
ILMN_1704537 PHGDH NM_006623 2 26227 2,18 6,63E-17
ILMN_1751598 SESN2 NM_031459 3 83667 2,18 3,36E-14
ILMN_3283772 LOC644237 XR_039184 1 644237 2,17 4,13E-15
ILMN_1761281 LOC441019 XM_498969 2 441019 2,16 6,39E-14
ILMN_1684158 GPT2 NM_133443 1 84706 2,16 4,22E-16
ILMN_1755749 PGK1 NM_000291 2 5230 2,16 6,62E-15
ILMN_1682717 IER3 NM_003897 8870 2,14 1,96E-14
ILMN_2121408 HBEGF NM_001945 1 1839 2,13 3,56E-16
ILMN_1722532 JMJD1A NM_018433 3 55818 2,13 3,26E-13
ILMN_1777513 KCTD11 NM_001002914 2 147040 2,12 1,18E-13
ILMN_2103547 GOLGA8B NM_001023567 2 440270 2,12 1,04E-13
ILMN_2098446 PMAIP1 NM_021127 1 5366 2,11 1,50E-15
ILMN_3242900 HIST2H2AA4 NM_001040874 1 723790 2,11 4,12E-14
ILMN_2144426 HIST2H2AA3 NM_003516 2 8337 2,07 5,59E-13
ILMN_1738407 ULBP1 NM_025218 2 80329 2,07 4,42E-14
ILMN_2322375 MAFF NM_012323 2 23764 2,07 1,77E-12
ILMN_1659047 HIST2H2AA3 NM_003516 2 8337 2,07 8,02E-16
ILMN_1685714 INHBB NM_002193 1 3625 2,06 2,98E-15
ILMN_1670875 PPM1D NM_003620 2 8493 2,06 6,09E-13
ILMN_1672350 JAM2 NM_021219 2 58494 2,05 2,41E-14
ILMN_1679727 CLK1 NM_004071 2 1195 2,03 2,36E-14
ILMN_1738742 PLAT NM_000930 2 5327 2,03 2,61E-15
ILMN_1704154 TNFRSF19 NM_148957 2 55504 -2,00 2,05E-14
ILMN_2167805 LUM NM_002345 3 4060 -2,01 7,60E-12
ILMN_2301083 UBE2C NM_181800 1 11065 -2,01 8,26E-15
ILMN_2053415 LDLR NM_000527 2 3949 -2,03 8,03E-15
ILMN_1810172 SFRP4 NM_003014 2 6424 -2,03 1,18E-12
EP 2 607 478 A1
24
5
10
15
20
25
30
35
40
45
50
55
(continued)
Table 2B DFO versus Bas filtered
ProbeID GeneName Refseq Entrez logFC(D142_ DFO - 
D142_BAS)
adj P Val(D142_D 
FO - D142_BAS)
ILMN_1756572 COQ2 NM_015697 6 27235 -2,03 3,02E-14
ILMN_1785891 PRKD1 NM_002742 2 5587 -2,05 6,65E-15
ILMN_2222008 KIFC1 NM_002263 2 3833 -2,05 2,86E-11
ILMN_1742981 TUBA1A NM_006009 2 7846 -2,06 6,31E-15
ILMN_1690170 CRABP2 NM_001878 2 1382 -2,06 6,27E-15
ILMN_2376953 KCNK2 NM_001017425 2 3776 -2,07 3,13E-14
ILMN_1765990 KCNK2 NM_001017425 2 3776 -2,07 1,48E-14
ILMN_2062701 GAS1 NM_002048 1 2619 -2,07 2,85E-15
ILMN_1810836 PDE5A NM_001083 3 8654 -2,08 6,53E-15
ILMN_1797728 HMGCS1 NM_002130 6 3157 -2,09 8,15E-13
ILMN_1812968 SOX18 NM_018419 2 54345 -2,09 1,13E-13
ILMN_1653711 FZD2 NM_001466 2 2535 -2,10 8,02E-15
ILMN_1812091 FAM20A NM_017565 2 54757 -2,11 8,42E-15
ILMN_2200836 HSPB7 NM_014424 3 27129 -2,12 2,99E-15
ILMN_1725090 CTHRC1 NM_138455 2 115908 -2,13 8,26E-16
ILMN_1696537 DDIT4L NM_145244 2 115265 -2,14 2,14E-13
ILMN_2349459 BIRC5 NM_001168 2 332 -2,14 2,03E-14
ILMN_1733094 STEAP1 NM_012449 2 26872 -2,15 1,65E-15
ILMN_1715508 NNMT NM_006169 2 4837 -2,16 2,33E-17
ILMN_1663575 MGC87042 XM_001128032 1 256227 -2,17 2,45E-15
ILMN_1686097 TOP2A NM_001067 2 7153 -2,19 1,17E-13
ILMN_1803825 CXCL12 NM_000609 4 6387 -2,19 6,04E-14
ILMN_1811909 LOC402221 XM_938988 1 402221 -2,22 1,70E-16
ILMN_1774602 FBLN2 NM_001998 2 2199 -2,23 1,70E-15
ILMN_1814998 FKSG30 NM_001017421 1 440915 -2,25 3,69E-16
ILMN_1770290 CNN2 NM_201277 1 1265 -2,29 4,69E-18
ILMN_2344283 FMO3 NM_001002294 1 2328 -2,30 4,06E-15
ILMN_1657683 C1orf198 NM_032800 1 84886 -2,30 5,69E-17
ILMN_1772612 ANGPTL2 NM_012098 2 23452 -2,31 5,71E-17
ILMN_1747016 CEP55 M_018131 3 55165 -2,32 4,25E-17
ILMN_2234956 LEPR NM_001003679 1 3953 -2,33 1,50E-15
ILMN_1786065 UHRF1 NM_001048201 1 29128 -2,34 8,87E-16
ILMN_2148785 GBP1 NM_002053 1 2633 -2,41 2,12E-15
ILMN_1702363 SULF1 NM_015170 1 23213 -2,42 1,70E-16
ILMN_1690125 PDLIM7 NM_213636 1 9260 -2,43 6,33E-15
ILMN_1700268 QPRT NM_014298 3 23475 -2,44 1,15E-15
ILMN_2117508 CTHRC1 NM_138455 2 115908 -2,46 5,25E-15
ILMN_1808657 FMO3 NM_006894 4 2328 -2,46 9,45E-16
ILMN_1790338 PRRX2 NM_016307 3 51450 -2,49 3,11E-17
ILMN_1784948 SPOCD1 NM_144569 4 90853 -2,53 7,09E-19
ILMN_2150894 ALDH1B1 NM_000692 3 219 -2,55 3,69E-16
ILMN_1789507 COL11A1 NM_001854 3 1301 -2,55 2,55E-16
ILMN_1733756 COL12A1 NM_080645 2 1303 -2,56 1,24E-15
ILMN_1791447 CXCL12 NM_199168 2 6387 -2,57 1,40E-16
ILMN_1671703 ACTA2 NM_001613 1 59 -2,61 1,43E-17
ILMN_1728934 PRC1 NM_199413 1 9055 -2,66 2,45E-18
ILMN_1765701 LOC399942 XM_934471 1 399942 -2,67 9,45E-17
ILMN_1744487 C1QTNF5 NM_015645 2 114902 -2,69 7,58E-18
EP 2 607 478 A1
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(continued)
Table 2B DFO versus Bas filtered
ProbeID GeneName Refseq Entrez logFC(D142_ DFO - 
D142_BAS)
adj P Val(D142_D 
FO - D142_BAS)
ILMN_1656057 PLAU NM_002658 2 5328 -2,69 6,84E-17
ILMN_1678493 CHN1 NM_001025201 1 1123 -2,71 2,13E-19
ILMN_1695658 KIF20A NM_005733 1 10112 -2,76 1,54E-18
ILMN_1727532 OLFML3 NM_020190 2 56944 -2,91 2,09E-19
ILMN_1689111 CXCL12 NM_000609 4 6387 -2,92 7,58E-18
ILMN_1772910 GAS1 NM_002048 1 2619 -3,12 4,83E-16
ILMN_2307903 VCAM1 NM_001078 2 7412 -3,16 1,12E-20
ILMN_1765557 OLFML2B NM_015441 1 25903 -3,16 2,90E-19
ILMN_1689088 COLEC12 NM_130386 1 81035 -3,20 7,53E-20
ILMN_1790529 LUM NM_002345 3 4060 -3,27 7,20E-21
ILMN_1663390 CDC20 NM_001255 2 991 -3,40 7,45E-19
ILMN_2234697 BEX1 NM_018476 3 55859 -3,45 1,32E-21
ILMN_1738116 TMEM119 NM_181724 1 338773 -3,83 1,84E-22
Table 2C HYP versus Bas filtered
ProbeID GeneName Refseq Entrez logFC(D142_HYP - 
D142_BAS)
adj P Val(D142_HYP 
-D142_BAS)
ILMN_1756573 NDUFA4L2 NM_020142 3 56901 2,36 1,50E-13
ILMN 2216852 PGK1 NM_000291 2 5230 1,75 7,24E-12
ILMN_1717990 CALD1 NM_033138 2 800 1,61 4,92E-10
ILMN_1775380 SMOX NM_175842 1 54498 1,52 1,06E-09
ILMN_2367258 SMOX NM_175840 1 54498 1,51 1,53E-09
ILMN_1850238 1,51 1,71E-08
ILMN_1706706 WDR68 NM_001003725 1 10238 1,48 1,02E-10
ILMN_1799569 LOC440895 XM_934629 1 440895 1,41 2,82E-09
ILMN_1755749 PGK1 NM_000291 2 5230 1,36 6,05E-09
ILMN_1755974 ALDOC NM_005165 2 230 1,31 2,02E-09
ILMN_1779258 LOC644774 XM_927868 1 644774 1,30 1,06E-09
ILMN_3305475 LOC729708 XM_001725700 1 729708 1,29 5,26E-09
ILMN_1695706 H3F3B NM_005324 3 3021 1,28 1,36E-09
ILMN_1668861 LOC732165 XM_001134259 1 732165 1,24 5,32E-08
ILMN_1807074 MIF NM_002415 1 4282 1,23 2,82E-09
ILMN_2189675 HRCT1 NM_001039792 1 646962 1,23 1,51E-07
ILMN_1691104 PGAM4 NM_001029891 2 441531 1,21 1,06E-07
ILMN_3277209 LOC285943 XR_040116 1 285943 1,21 1,11E-07
ILMN_1684114 LOC286016 NR_002187 2 286016 1,21 2,82E-09
ILMN_1792495 AHNAK NM_001620 1 79026 1,19 5,94E-08
ILMN_1886487 1,19 2,49E-08
ILMN_1752159 AHNAK NM_024060 2 79026 1,18 4,28E-09
ILMN_1728059 LOC645236 XM_928275 1 645236 1,18 1,31E-07
ILMN_2338038 AK3L1 NM_013410 2 205 1,17 1,31E-08
ILMN_1661366 PGAM1 NM_002629 2 5223 1,17 3,60E-07
ILMN_3267451 GAPDHL6 XM_001726954 1 729403 1,16 5,94E-08
ILMN_1790741 RNF126 NM_194460 1 55658 1,16 1,78E-07
ILMN_1660654 CDCA2 NM_152562 2 157313 1,13 2,68E-08
ILMN_2366719 NSFL1C NM_182483 1 55968 1,12 5,10E-07
ILMN_1674661 CIRBP NM_001280 1 1153 1,12 8,21E-09
ILMN_2173451 GPI NM_000175 2 2821 1,11 2,33E-07
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(continued)
Table 2C HYP versus Bas filtered
ProbeID GeneName Refseq Entrez logFC(D142_HYP - 
D142_BAS)
adj P Val(D142_HYP 
-D142_BAS)
ILMN_3283772 LOC644237 XR_039184 1 644237 1,08 3,02E-07
ILMN_1663042 SDC4 NM_002999 2 6385 1,08 1,12E-06
ILMN_1707627 TPI1 NM_000365 4 7167 1,08 3,47E-07
ILMN_1791002 SKP2 NM_005983 2 6502 1,08 2,34E-05
ILMN_1747160 SYT15 NM_181519 2 83849 1,05 1,02E-06
ILMN_1735955 LOC644033 XM_927280 1 644033 1,05 1,74E-07
ILMN_1764090 AK3L1 NM_203464 1 205 1,04 3,06E-06
ILMN_2112417 PGAM1 NM_0026292 2 5223 1,04 1,98E-06
ILMN_1682953 PGAM4 NM_001029891 2 441531 1,03 1,06E-07
ILMN_1790562 EYA3 NM_001990 2 2140 1,03 8,00E-07
ILMN_1793543 C1orf51 NM_144697 2 148523 1,03 9,09E-07
ILMN_1669667 PDLIM2 NM_198042 2 64236 1,03 2,06E-06
ILMN_1659703 WWP2 NM_199423 1 11060 1,03 4,40E-07
ILMN_1772876 ZNF395 NM_018660 2 55893 1,02 1,33E-07
ILMN_2143155 KIF11 NM_004523 2 3832 1,02 9,87E-08
ILMN_1724658 BNIP3 NM_004052 2 664 1,01 1,70E-08
ILMN_3301740 LOC729887 XR_040891 1 729887 1,01 1,89E-05
ILMN_1693334 P4HA1 NM_000917 2 5033 1,01 6,01E-06
ILMN_3305938 SGK1 NM_005627 3 6446 -1,01 6,85E-08
ILMN_3240314 SCXA NM_001008271 1 1E+08 -1,02 6,50E-06
ILMN_1685854 C5orf53 NM_001007189 1 492311 -1,03 9,30E-08
ILMN_1789507 COL11A1 NM_001854 3 1301 -1,03 1,82E-06
ILMN_1754969 LMCD1 NM_014583 2 29995 -1,03 9,73E-09
ILMN_1664776 EFR3A NM_015137 3 23167 -1,03 1,03E-07
ILMN_1679476 GART NM_000819 3 2618 -1,04 2,32E-07
ILMN_1667825 MLKL NM_152649 1 197259 -1,04 5,38E-06
ILMN_1805561 SLC14A1 NM_015865 2 6563 -1,04 2,33E-07
ILMN_1663631 BANP NM_079837 2 54971 -1,04 5,72E-08
ILMN_2397750 IVNS1ABP NM_006469 4 10625 -1,04 7,83E-07
ILMN_2330570 LEPR NM_001003680 1 3953 -1,05 1,16E-07
ILMN_1797684 PDCD2 NM_002598 2 5134 -1,05 2,88E-07
ILMN_2300186 DYNLL1 NM_001037494 1 8655 -1,06 1,18E-06
ILMN_1696537 DDIT4L NM_145244 2 115265 -1,06 5,38E-06
ILMN_1702487 SGK NM_005627 2 6446 -1,06 5,72E-08
ILMN_1740426 RASD1 NM_016084 3 51655 -1,07 6,09E-07
ILMN_1795227 DNCL1 NM_003746 1 8655 -1,07 1,13E-07
ILMN_2103591 MORC2 NM_014941 1 22880 -1,07 1,11E-06
ILMN_2269564 ARID4B NM_016374 5 51742 -1,07 1,21E-07
ILMN_2044617 MTERFD1 NM_015942 3 51001 -1,08 9,32E-07
ILMN_1754489 FBXL20 NM_032875 1 84961 -1,08 1,03E-07
ILMN_3229324 SGK1 NM_005627 3 6446 -1,09 4,14E-07
ILMN_1676588 CEPT1 NM_001007794 1 10390 -1,09 1,79E-07
ILMN_1743104 RBM4B NM_031492 2 83759 -1,10 1,06E-07
ILMN_1737580 PPPDE2 NM_015704 1 27351 -1,10 5,94E-08
ILMN_1735360 SDAD1 NM_018115 2 55153 -1,10 5,59E-09
ILMN_2234187 CDO1 NM_001801 2 1036 -1,10 2,57E-07
ILMN_1694847 TERF1 NM_017489 1 7013 -1,11 2,75E-08
ILMN_3274596 LOC286512 XR_038196 1 286512 -1,11 4,69E-06
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Claims
1. A method for culturing mesenchymal stromal cell (MSC), the method comprising:
- providing a MSC; and
- culturing said MSC in the presence of 1, 10-phenanthroline or an active derivative thereof;
2. A method according to claim 1, the method further comprising harvesting the thus cultured cell(s) and/or a supernatant
thereof.
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3. A method according to claim 1 or 2, wherein the duration of culturing said MSC in the presence of 1, 10-phenanthroline
or the active derivative thereof is for at least 12 hours.
4. A collection of cells and/or a supernatant, obtainable by a method according to claim 2 or 3.
5. A collection of cells according to claim4 and/or a supernatant according to claim 4, for use as a medicament.
6. A collection of cells and/or supernatant according to claim 4, for use in treating ischemia, for use in treating oste-
oporosis, for use in treating bone fractures, for inducing angiogenesis, for accelerating wound healing, for accelerating
tendon regeneration, and/or for accelerating ligament regeneration.
7. Use of 1, 10-phenanthroline or an active derivative thereof for improving the angiogenic properties of a MSC and/or
supernatant thereof, for inducing differentiation in a MSC, and/or for improving the angiogenic properties of a medical
product.
8. Use according to claim 7, wherein said MSC is induced to differentiate into an endothelial (precursor) cell, an
osteoblast (precursor) cell, a tendon precursor cell, or a ligament precursor cell.
9. Method for treating a subject, the method comprising: administering to said person a suitable amount of cells and/or
supernatant according to claim 4.
10. Method according to claim 9, wherein said subject is in need of angiogenesis, in need of treatment for ischemia, in
need of wound healing, in need of tendon regeneration, in need of beta cell islets and/or in need of ligament
regeneration.
11. A medical product comprising 1, 10-phenanthroline and/or an active derivative thereof, cells according to claim 4,
and/or supernatant according to claim 4.
12. The medical product of claim 11, wherein said medical product is a suture, a patch, a wound dressing, a pump, a
plug, an implant or a graft.
13. The medical product according to claim 11 or 12 for use in replacing a missing biological structure, supporting a
damaged biological structure, or enhancing an existing biological structure.
14. A method for replacing a missing biological structure, supporting a damaged biological structure, and/or enhancing
an existing biological structure, the method comprising the use of cells according to claim 4, supernatant according
to claim 4, 1, 10-phenanthroline or an active derivative thereof, and/or a medical product according to any one of
claims 11-13, to replace, support or enhance a biological structure.
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